EUREKA Institute

International Certificate Program
April 23rd - 29th, 2017
Siracusa, Italy
The Three Pillars

The Eureka educational initiative is based on:
- an attitude of teamwork
- critical thinking skills
- knowledge of translational medicine

Eureka’s mission

The Institute’s mission is to develop a community of translational medicine professionals equipped to catalyze the application of discoveries for the benefit of human health. We do this by educating and building a community.

Overall Educational Objectives

Participants in the Certificate Program will:

1. Analyze the business, scientific and regulatory aspects of Translational Medicine (TM)
2. Explore the challenges professionals encounter in TM
3. Develop critical thinking skills to approach the challenges in Translational Medicine
4. Develop communication skills for presenting various topics to a broad spectrum of people

Educational Strategies

We use a number of educational strategies to achieve the overall course objectives and the goals of each individual activity. Key among these is creating an open and safe environment through which participants can navigate, and in which participants may interact.
Support

We thank the kind support of our partners: University Medical Center Utrecht, SingHealth Duke–NUS Academic Medical Centre, University of Arizona, University of Miami, Stanford University Medical Centre, and supporters: University College London, Parent Project Muscular Dystrophy, Danone Nutricia Research, Nature Medicine and Nature Medicine Biotechnology.

We deeply appreciate the Faculties for the 2017 International Certificate Program. They are generously donating their time and expertise to participate in the course. Our sincere gratitude goes to Julia Ong, who provides energy and cohesion to this Program. In addition, we thank our Artists-in-Residence Anna van Suchtelen and Brian Goeltzenleuchter for contributing their time and passion in cultivating the 2017 Translational Creativity program. Lastly, we thank Francesco Italia, Vittorio di Natale, and their colleagues at the Borgia del Casale for their extraordinary efforts, and for the beautiful space in which the course is held.

Eureka Board of Directors
Salvatore Albani, President & Treasurer
Berent Prakken, Secretary/CEO
Norman Rosenblum, Chairman of BoD

Members
Vicki Seyfert-Margolis
David Hafler
Janet Hafler
Maria Grazia Roncarolo

Edited and compiled by The Eureka Institute for Translational Medicine

A publication of the Eureka Institute for Translational Medicine. Prepared in the partial fulfillments of the requirements for the certificate of completion. Continuing Medical Education credits are not being offered for this course, however the materials are in compliance with the requirements of the Accreditation Council for Continuing Medical Education. Course materials and handouts include edited and compiled works of multiple authors.

Reproduction of this document or any part thereof, or the additional materials offered throughout the course is governed by Italian copyright law no. 633 of April 22, 1941. Copying material contained in this document or other course materials for general distribution, for advertising or promotional purposes, for resale, for creating new collective works, or for commercial proprietary purposes, is strictly prohibited.

Requests for reprints or reproduction to:
Eureka Institute for Translational Medicine
Ms Julia Ong
c/o STIIC, The Academia, Discovery Tower Level 8
20 College Road
Singapore 169856
info@eurekainstitute.org

© 2017 Eureka Institute for Translational Medicine
All Rights Reserved
About Translational Medicine

Today, the term “translational medicine” is a buzzword in biomedical sciences with a rapidly increasing number of meetings about it; courses on it; and institutes dedicated to it. A simple Pubmed search on “translational medicine” generates over 77,000 papers, while a Google search yields nearly 9,000,000 hits. Because of its popularity and its increased use, the meaning of the term translational medicine has become progressively ambiguous and is often used synonymously with clinical testing.

In our opinion, translational medicine encompasses the continuum of activities that extend from the conception of an idea all the way into Phase II/III clinical testing and, ultimately, the development of a tangible product. This itinerary includes multiple and diverse components requiring very different skills and competencies ranging from molecular medicine to pharmacology; from animal testing to clinical trial design; from intellectual property to venture capital.

Translational medicine is therefore the framework needed to ensure the evolution of novel technologies into tangible benefits for patients.

About the Program

You will find in the following pages:
- a brief introduction to Eureka and Translational Medicine
- basic logistical information
- course materials organized by day
- faculty, artists’ and participants’ bios

This is a living document that will grow and change with you as you move through the course. Because we focus on active participation rather than passive processes, the program will be tailored to your needs and expectations, both the ones pre-defined and those that arise in situ. The program materials are organized chronologically. For each session, you will find an abstract as well as its principal learning objectives.

Each day will start at 8:15 with coffee and brief social period, which will segue into the first session of the day (at 8.30am). The course is balanced between didactic sessions, interactive discussion, and practical application. Please make opportunities to synthesize the discussions and explore, in a personal context, how the topics covered can be applied to your own work.

Evaluation of the course is an important part of reflecting on the experience and providing feedback aimed at course improvement. You will be provided with an e-based evaluation that can be completed on an ongoing basis throughout the course and should be submitted by the end of the course.
Eureka Faculty Roster - April 2017

Salvatore Albani, MD, PhD,
Professor, Duke-NUS Medical School Singapore, Director, SingHealth Translational Immunology and Inflammation Centre, UCAN-A Chair

Manuela Battaglia, PhD,
Deputy Director San Raffaele Diabates Research Institute - Milano (IT)

Valeria Drago MD, PhD, Clinical Neurologist, Muscataello Hospital, Augusta, Siracusa, Italy

Wainwright Fishburn, JD,
Partner, Cooley LLP

Patricia Furlong, RN, BS, MS,
Founding President and Chief Executive Officer, Parent Project Muscular Dystrophy

Carol Gregorio, PhD,
Luxford/Schoolcraft Professor, Professor and Head of Cellular and Molecular Medicine; Co-Director, Sarver Heart Center; Director, Molecular Cardiovascular Research Program; Vice Dean for Innovation and Development, College of Medicine @ the University of Arizona

Brian Goeltzenleuchter, MFA,
Artist-in-Residence

David Hafler, MD,
Chief and Chair of Neurology, Yale New Haven Hospital and Yale School of Medicine

Janet Hafler, EdD,
Professor of Pediatrics, Associate Dean for Educational Scholarship, Yale School of Medicine

Giovanni Licciardello, MD,
Contract Professor at Graduate Cardiology School, Catania University

Patrick Maxwell, MD,
Regius Professor of Physic and Head of the School of Clinical Medicine, University of Cambridge

Frank Miedema, PhD,
Dean and Vice Chairman of the Board and professor of Immunology, University Medical Centre Utrecht, the Netherlands

Steven Myint, MD, PhD,
Chairman, Inex Private Ltd, Singa-pore (Medtech); Chairman, Flexpress Oy & Inc (Finland & USA) (Medtech); Founding Partner, Innovatum Accelerator & Ukkopartners (IT and Biotech investments), Finland; General Partner, Pharma Capital (Biopharma Venture capitalism); Senior Fellow & Strategic Consultant on commercialisation, A*star, Singapore (Government Research Agency); Scientific Advisor, European Centre for Disease Control, Belgium

Martin Offringa, MD, PhD,
Senior Scientist and Program Head, Child Health Evaluative Sciences CHES, Research Institute, The Hospital for Sick Children, Staff Neonatologist, Department of Paediatrics, Professor of Paediatrics, University of Toronto

Berent Prakken, MD, PhD,
Professor of Paediatric Immunology, University Medical Centre Utrecht; Chair Research and Education Division Pediatrics, Co-Chair, UCAN-U;Chair, ENTRAIN

Sergio A. Quezada, PhD,
Group Leader, Immune Regulation and Tumour Immunotherapy Lab CRUK Senior Cancer Research Fellow UCL Cancer Institute

George M. Rehm, BSFS, JD,
Partner EVP Capital, Venture Partner, EMBL Ventures, former founding partner, aeris CAPITAL AG.

Risicato Roberto, MD,
Director of Internal Medicine Unit with Unit of Neurology and Unit of Emergency, at Augusta (SR) Hospital

Norm Rosenblum, MD, FRCP, Professor of Paediatrics, Tier I Canada Research Chair in Developmental Nephrology, and Associate Dean, Physician Scientist Training, University of Toronto

Maria Grazia Roncarolo, MD,
George D. Smith Professor of Paediatrics and Medicine, Division Chief, Paediatric Stem Cell Transplantation and Regenerative Medicine, Co-Director, Bass Center for Childhood Cancer and Blood Diseases, Co-Director, Institute for Stem Cell Biology and Regenerative Medicine, Department of Paediatrics, Stanford School of Medicine

Salmaan Sana,
Change Agent/Consultant, Better Future Coach, Facilitator and Program Designer

Vicki Seyfert-Margolis, PhD,
Founder and CEO, My Own Med, Inc.

Anita Small, MSc, EdD,
Founder and owner of Small Language Connections

Nancy Sweitzer, MD, PhD,
Director, Sarver Heart Center, Chief, Division of Cardiology, University of Arizona College of Medicine

Uri Tabori, MD,
Staff NeuroOncologist, Division of Haematology/Oncology, Associate Professor of Paediatrics, University of Toronto, Senior Scientist, Research Institute and The Arthur and Sonia Labatt Brain Tumour Re-search Centre The Hospital for Sick Children

Timothy J. Triche, MD, PhD,
Professor, Pathology & Pediatrics Keck School of Medicine at USC Co-Director, Center for Personalized Medicine at Children’s Hospital Los Angeles

Thorsten Vetter, MD,
Clinical Pharmacologist Senior Scientific Officer - Scientific Advice European Medicines Agency, United Kingdom

Lucy R Wedderburn FRCP, PhD,
Professor and Consultant of Paediatric Rheumatology, Director, Arthritis Research UK Centre for Adolescent Rheumatology at UCL, UCLH and GOSH, Deputy Director, NIHR Great Ormond Street Biomedical Research Centre, UCL GOS Institute of Child Health, University College London
Observer Faculty

Mary Chen, MS, MBA,
Assistant Dean, Maternal Child Health Research, Stanford University School of Medicine; Administrative Director, Stanford Child Health Research Institute; Director, Spectrum Child Health, Stanford Center for Clinical and Translational Research

Alessia Fornoni, MD, PhD,
Peggy and Harold Katz Family Professor of Medicine
Chief, Katz Family Division of Nephrology and Hypertension
Director, Peggy and Harold Katz Drug Discovery Center
University of Miami Miller School of Medicine

Karel G.M. Moon (Carl), PhD,
Professor, Clinical Epidemiology and Director of Research, Julius Center for Health Sciences and Primary Care, UMC Utrecht, The Netherlands. Adjunct Professors, Vanderbilt University, Nashville, USA. Editor in chief of BMC Diagnostic & Prognostic Research.

Kee Chong Ng, MD,
Associate Professor of Paediatrics, Chair Division of Medicine; Campus Director Medical Innovation & Care Transfor-mation, KK Women’s and Children’s Hospital; Chair, Academic Clinical Program (Paediatrics) SingHealth-DukeNUS

Rosalind L Smyth, CBE, MA MBBs, MD, FRCPCH, FMedSci,
Director and Professor of Child Health, UCL Great Ormond Street Institute of Child Health.

Introduction e-learning module for Translational Medicine

The Eureka course started with an online introduction prior to the face-to-face course in Siracusa in May since 2014 course. The course was developed by Eureka Faculty (coordinated by Juan Carlos Lopez and Sylvia Brugman), a 2010 Eureka alumnus together with Davey van de Heijden and Renee Filius (both at Elevate health). It was made possible thanks to generous support from EUTRAIN and the Child Health program of the UMCU.

Elevate Health is an online academy that educates international health professionals, elevating professional knowledge and improving health worldwide. This online e-learning course (e-course) aims to get everyone up to speed with regards to the definition and components of Translational Medicine before the participants arrive at the face to face course.
Sunday, April 23rd

Coffee
Time: 8:15 - 8:30

Welcome and introductions
Facilitator: Janet P. Hafler
Time: 8:30 - 10:00

Introduction of curriculum
Facilitator: Norman Rosenblum and Carol Gregorio
Time: 10:00 - 10:10

Break, 10:10 - 10:25

Mapping Translational Medicine
Presenters: Berent Prakken
Time: 10:25 - 11:45

Abstract
In this session, the objectives of the course and concepts of translational medicine will be introduced and defined.

Objectives
1. Define the field of translational medicine
2. Analyse the components involved
3. Discuss the challenges of translational medicine

Connect Before You Lead
Facilitator: Salmaan Sana
Time: 11:45 - 12:30

See the “Team Building and Social Impact” page on 22 for overview

Group Lunch, 12:30 - 13:30

Communication Styles Reflection
Facilitator: Anita Small
Time: 13:30 - 13:45

Abstract and Objective
Complete Communication Styles Questionnaire. Refer to session on Monday April 4, when questionnaire will be scored, analyzed and applied to professional collaboration.

Introduction to Teaching and Learning
Presenter: Janet P. Hafler
Time: 13:45 - 14:30

Abstract
In this session teaching to promote learning will be discussed. In particular, we will explore how to learn in case based discussions. The participants will begin to use their journals to promote self reflection focused on teaching and learning.

Objectives
1. Explore how teaching can promote learning.
2. Explore strategies of effective teaching.
3. Develop observational skills and observe teaching.
4. Discuss a variety of teaching formats.

“Sisyphus”, A Case Study
Facilitator: Norman Rosenblum
Written by: Salvatore Albani and Jessica Colomb
Time: 14:30 - 15:30

Abstract
“Sisyphus” is based on a real case about the development of a novel immunotherapeutic strategy. It focuses on compounds designed specifically for humans. Sisyphus addresses typical problems in proof-of-concept studies, development and regulation. This case also prevents incongruities in animal models of disease versus human application.

Objectives
1. Explore strategies for lead identification
2. Explore strategies for chemistry, manufacturing and controls (CMC) studies (funding and conduct)
3. Explore strategies for safety data in untraditional models

Break, 15:30 - 15:45

From Discovery to Clinical Trial: the Translational Pathway
Presenter: Maria Grazia Roncarolo
Time: 15:45 - 16:30

Abstract
Investigators developing technologies in an academic setting need to have the tools to evaluate the options that are available to them, when to utilise academic resources, and when to seek other options. This session will examine the TM itinerary in relation to the respective roles of academia, IP, patents and technology transfer.

Objectives
1. Explore the pathway of IP development within an institution
2. Discuss the benefits and detriments of technology transfer
3. Discuss the options, obligations, and strategies of the investigator

Mapping Translational Medicine
Presenters: Berent Prakken
Time: 10:25 - 11:45

Abstract
In this session, the objectives of the course and concepts of translational medicine will be introduced and defined.

Objectives
1. Define the field of translational medicine
2. Analyse the components involved
3. Discuss the challenges of translational medicine

Connect Before You Lead
Facilitator: Salmaan Sana
Time: 11:45 - 12:30

See the “Team Building and Social Impact” page on 22 for overview

Group Lunch, 12:30 - 13:30

Communication Styles Reflection
Facilitator: Anita Small
Time: 13:30 - 13:45

Abstract and Objective
Complete Communication Styles Questionnaire. Refer to session on Monday April 4, when questionnaire will be scored, analyzed and applied to professional collaboration.

Introduction to Teaching and Learning
Presenter: Janet P. Hafler
Time: 13:45 - 14:30

Abstract
In this session teaching to promote learning will be discussed. In particular, we will explore how to learn in case based discussions. The participants will begin to use their journals to promote self reflection focused on teaching and learning.

Objectives
1. Explore how teaching can promote learning.
2. Explore strategies of effective teaching.
3. Develop observational skills and observe teaching.
4. Discuss a variety of teaching formats.
Sunday, April 23rd cont.

Introduction to mentoring: Preparing for your mentoring groups
Time: 16:30 - 16:45
Facilitators: Janet P. Hafler and all mentoring faculty

Goal
To prepare both faculty and participants for participation in the mentoring groups

Objective
1. To discuss effective mentoring
2. To explore strategies to facilitate discussion in the groups

Mentoring Session I
Time: 16:45 - 18:15

Abstract and Goals
As part of the course, participants will present a dilemma they are currently facing to a small group of peers. This group will be mentored by faculty. Fellow course participants will act as a consultation group. The objective is to advance personal learning while practicing and improving approaches to, and organization of, problem solving. Reflections using practical real-world problems will anchor the concepts raised in the didactic portion of the program.

Sunday Social Program

19:30 Tour of the Borgia del Casale

20:00 Opening Dinner @ Porta Marina - de Salvo, via dei Candelai, 35, Ortigia
(Gather at Borgia, Smin walk)

Please join us to celebrate the 9th Annual International Certificate Program in Translational
Monday, April 24th

Coffee
Time: 8:00 - 8:15

Debriefing
Facilitator: Janet P. Hafler
Time: 8:15 - 8:45

Communication Styles: Strengths and Team Effectiveness
Facilitator: Anita Small
Time: 08:45 - 9:30

Abstract
Through analysis of a Communication Styles Questionnaire used by international mediators, participants will discover their strengths in communication interaction. A model for applying these strengths to problem solving, conflict situations and collaboration in team settings is discussed. Personal insights may be applied to translational medicine collaborations for social impact.

Objectives
1. Score the Communication Styles Questionnaire to your style
2. Increase knowledge of different styles of interaction and their roles in problem solving and collaboration.
3. Increase your awareness of the communication strengths you bring to effective group problem solving and collaboration

Let Us Get Working
Facilitator: Salmaan Sana
Time: 9:30 - 11:30

The Patient in Translational Medicine
Presenter: Patricia Furlong
Time: 11:30 - 12:30

Abstract
Patients and family members, when faced with a catastrophic diagnosis (rare or otherwise) feel isolated and alone. The dreams and plans for the life they imagined are gone. Parents with sick children feel as if they have failed parenthood, no longer able to ‘fix’ things or dry every tear. As parents, we have few choices and by default, necessarily become an advocate. We search the internet, sign up for Google alerts, connect on Facebook and Twitter. We join registries or develop new ways to collect qualitative and quantitative data. We travel across the world to identify physicians with expertise and interdisciplinary care. We solicit interested researchers to characterize the disease of interest. We start foundations, partner with industry and fund start-up companies. We become caregivers, caretakers, investors and partners. We are the new generation: Citizen Scientists. We educate family, extended family, school, community and every individual that crosses our path. We learn the language of science, drug development and medicine. We drive regulatory change and healthcare policy. We are aggressive, fearless and effective. Our only interest is to change the world.

Objectives
1. Discuss trajectory of a pediatric rare disease diagnosis
2. Identify opportunities and time points for intervention, support, engagement
3. Discuss the ecosystem of rare diseases and opportunities for partnership between healthcare professionals, researchers, parents/family members and the biopharmaceutical industry

Let Us Get Working
Facilitator: Salmaan Sana
Time: 9:30 - 11:30

See “Team Building and Social Impact” page on 22 for overview
Monday, April 24th cont.

Group Lunch, 12:30 - 13:45

Stories of Success in Translational Medicine - Part 1 (Text in Blue & Bold)
Presenter: Maria Grazia Roncarolo, Tim Triche, Vicki Seyfert-Margolis and Martin Offringa
Time: 13:45 - 15:45

Abstract
Clinicians and entrepreneurs who have successfully taken ideas from the research laboratory to the clinic will discuss their stories of how they successfully navigated the science, business and administrative challenges involved in translational medicine. The session will include examples of new product development, changes in clinical practice and technology. They will also feature different models of how to work in translational medicine - new company, within a university or hybrid models

Break, 15:45 - 16:00

Stories of Success in Translational Medicine - Part 2 (Text in blue and Bold)
Presenter: Maria Grazia Roncarolo, Tim Triche, Vicki Seyfert-Margolis and Martin Offringa
Time: 16:00 - 17:15

Abstract
see above

Break, 17:15 - 17:30

Keynote encounter: The True Story of Sisyphus
Presenter: Salvatore Albani
Time: 17:30 - 19:00

This encounter will have a guided and an open session:
In the guided session, the challenges, failures and success of the itinerary from creativity to product will be unveiled in an intimate, personal and self-biographic fashion. Particular emphasis in this part will be given to the personal issues, choices, mistakes and intuitions which have been experienced first hand. A clear path forward will be depicted, and the peculiarities of developing a first in class drug discussed.

In the open discussion session, there is opportunity to delve in specific details and discuss them.

(In Session Wine and Cheese)

Monday Social Program

Wine and Cheese
19:15 - 20:30
@Borgia’s court yard

Introduction to Translational Creativity:
Artists/Facilitators: Anna van Suchtelen and Brian Goeltzen-leuchter
Tuesday, April 25th

Coffee
Time: 8:15 - 8:30

Debriefing
Facilitator: Janet P. Hafler
Time: 8:30 - 9:00

The concept of druggability: Translational value of a discovery: Why should it go into our patients?
Presenter: Salvatore Albani
Time: 9:00 - 10:00

Abstract
This encounter will distill from the keynote encounters of the previous day the common elements related to identifying, nurturing and developing an idea. The content will evolve from self biographic to more analytical and objective. Specifically, the concept of what makes a discovery attractive for translational developments, what it takes, with whom one associates, what objective parameters are considered by the various stakeholders will be defined.

Break, 10:00 - 10:15

Pre-Market Product Development: Interactive exploration of clinical trial design and product development
Presenter: Vicki Seyfert-Margolis and Thorsten Vetter
Time: 10:15 - 11:45

Abstract
A background on the latest trends in pre-market product development including biomarkers, diagnostics, devices, drugs and biologics will be discussed with respect to the applied science of product development needed to move more innovative products to the market for patients who need them. Various aspects involved in the science needed to improve product development, from pre-clinical to clinical trials will be described as well as the latest policies under discussion in the United States and Europe.

Objectives
1. Discuss the latest trends, gaps and opportunities in the applied science of product development and evaluation (regulatory science).
2. Describe the stakeholders, priorities and up to date efforts on-going in regulatory science.
3. Examine the various policy discussions surrounding pre-market product development from discovery to market launch, including funding, regulatory, reimbursement, and other considerations.

Group Lunch, 11:45 - 13:00

Patents
Presenter: George Rehm
Time: 13:00 - 14:00

Abstract
To patent or not to patent that is the question? We will explore patents in depth, including differences between countries, what patents protect and what they don’t, and other practical advice for the how, why and when to patent or not.
Tuesday, April 25th cont.

Unfolding Case Study 1: The Magic Bullet
Written by: Vicki Seyfert-Margolis
Time: 14:00 - 15:00

Abstract
This case examines the full translational tightrope of a targeted therapy, from lead identification to Phase II and III clinical trials. Participants will work in depth with the case in a small group setting over three separate sessions.

Recommended reading will be provided:

Objectives
Through this case, participants will grapple with the development of a therapy intended for a targeted sub-population, and explore the issues arising in the post-market phase. In addition, participants will discuss and determine research and business strategies necessary to "translate" a potential therapeutic, and co-develop its companion biomarker. Parallel concepts of collaboration and team will also be explored.

Break, 15:00 - 15:15

Presenting Preparation and Workshop I
Time: 15:15 - 17:15

Abstract
Participants will be given a 5 minutes presentation. Peers and faculty will critique the presentation and the presenter will self-evaluate.

Objectives
1. Evaluate the best methods for delivering a message
2. Explore strengths and areas of improvement in your personal presentation style
3. Develop presentation/communication skills

Break, 17:15 - 17:30

Speed Dating I
Time: 17:30 - 19:00 (Starts promptly at 17:30)

Abstract and Objectives
“Speed dating” provides the opportunity for participants to have a series of one-on-one discussions with individual faculty for 10 minutes each. Topics are the participant’s choice. Please consult the faculty biographies at the end of this program prior to completing the signup sheet, which will be prominently displayed and made available from Sunday.

Effective presenting format
A. Start with a brief statement of the goal to be addressed in your presentation and indicate who you consider to be the target audience.
B. Present for up to five minutes. Your colleagues will participate as the audience and the presentation will be videotaped.
C. 1) You, the presenter, will then view the videotape on your own and, as it plays and for a short time after, develop a list of strengths and suggestions for personal improvement.
2) While the presenter views the tape, the "audience" of colleagues discusses the strengths of the presentation and suggestions for improvement. Suggestions should
• Deal with behavior, not with the person.
• Focus on strengths as much as possible.
D. The presenter and the audience reconvene, each providing feedback on strengths and suggestions. The purpose of this discussion is to:
• allow for self-reflection on the part of the presenter and feedback in the context of suggestions for future teaching.
• define and authenticate issues in teaching.
• provide an occasion for others to help if appropriate.

You will present for up to 5 min. (and be videotaped)

Review your video on your own (5 min.)

Group discusses and critiques the presentation

You return to group comment on your review receive feedback (5 min.)

The Presentation Workshop
Observation Guide

Process
1. How does the presentation begin?
   - How does the presenter capture attention and promote curiosity?
   - How is the overview presented?
2. Is the information presented in a well organized manner?
3. Presentation: Is the delivery paced to the audience's capacity to follow?
   - Does the presenter avoid reading notes?
   - Does the presenter show any distracting mannerisms?
   - Did the presentation start and end on time?
4. How does the presenter promote active participation? Does he/she
   - use movement?
   - make eye contact with the audience?
   - use aids?
   - ask questions that prompt reflection or response?
   - use buzz groups, voting or brainstorming?
   - problem solve?
5. How does the presentation conclude?
   - Is there a review?
   - Are there follow-up tasks?
   - Is there an evaluation (the one-minute paper)?
6. How is learning assessed?

Content
1. Is the content accurate?
2. Does the presenter show a relationship between theory and practice?
3. Is the level of the material appropriate to the audience?
4. Was the presentation complete?
Feedback Tips

**Definition**
The process of giving data back to the participant for the purpose of bringing about change.

Feedback involves responding specifically to an event or occurrence, whether that event be good or bad. Positive and negative feedback should be distinguished from complimenting and criticizing.

Evaluation is an assessment of a learner's achievement and/or performance.

1. Feedback should be undertaken with the observer and participant working as allies with common goals. Begin by discussing respective expectations.
2. Feedback should be descriptive rather than evaluative.
3. Feedback should deal with specific events, rather than generalizations.
4. Feedback should be well-timed, and expected, in close proximity to the event, but not when — the recipient is postcall or angry about the issue; facts are missing; or both sides of the situation have not been explored.
5. Feedback should be based on first-hand data.
6. Feedback should be focused on behaviors that are amenable to change.
7. Feedback should involve sharing of information, rather than giving advice, leaving the receiver free to decide for themselves in accordance with their own goals and needs.
8. Feedback can be structured to include subjective data, as long as it is clearly labeled as such.
9. Feedback should be checked to insure clear communication by having the receiver try to rephrase the feedback.
10. Feedback should be followed by attention to the consequences of feedback.

**Taking the Plunge**
1. Be clear about the purpose of the feedback session.
2. Get the receiver's perspective as to how things are going.
3. The sandwich technique (i.e., good / bad / good) isn't always reliable.
4. Ask the recipient to offer solutions.
5. Develop solutions to the problem, and a plan to improve the situation.
Wednesday, April 26th

Coffee
Time: 8:15 - 8:30

Debriefing
Facilitator: Janet P. Hafler
Time: 8:30 - 9:00

Theory behind creativity
Facilitator: Berent Prakken
Time: 9:00 - 9:15

“When to Throw a painting to a Drowning Man: an introduction on Translational Creativity”
Artists/Facilitators: Anna van Suchtelen and Brian Goeltzenleuchter
Time: 09:15 - 12:00

Abstract
We like to think that artwork operates like a speed bump that sits casually in the street; not only because it seems to enjoy its ordinary status - privileging those who notice it and gently punishing those who don’t - but because the reaction it generates in the people who run across it seems to say a lot about their comfort level with the things that inevitably happen in life. As artists, we conduct events designed to destabilise – to function outside of the socially-prescribed behaviour of artwork; we attempt to test propositions without coercing prescribed outcomes. The forms that our work takes include participatory events and environments, scripted and improvised performances, photography and video and olfactory art. As such, we privilege the aesthetic moment over the aesthetic object.

Paintings for Drowning Men: A workshop on translational creativity is a series of participatory art workshops based on the video When to Throw a Painting to a Drowning Man, commissioned by Eureka Institute for Translational Medicine in 2011.

Objectives
Creating a workshop environment in which participants, can indulge in creative “tasks” which may include cooking, drawing, singing, dancing, as well as other participatory forms. 1 The tone of the project shifts between the comical, the philosophical, and the therapeutic. Ultimately, it is a celebration of the transcendent nature of creativity in our daily lives.

In session break

Group Lunch, 12:00 - 13:30

Drug development
Presenters: Vicki Seyfert-Margolis
Time: 13:30 - 15:00

Abstract
Predictive markers, toxicology models, and tools to help shape intelligent drug design and diagnostic development will be explored.

Objectives
1. Identify state of art technologies for predicting toxicology and efficacy
2. Discuss use of the above to optimise the development of new therapies

Break, 15:00 - 15:15

Unfolding Case Study 2 - The Magic Bullet (continued)
Written by: Vicki Seyfert-Margolis
Time: 15:15 - 16:30

Introduction of Presentation Workshop II
Facilitator: Norman Rosenblum and Patrick Maxwell
Time: 16:30 - 16:45

Small Piece, Big Pie
Presenters: Berent Prakken and Sergio Quezada
Time: 16:45 - 18:00

Abstract
This interactive seminar will explore the challenge of individual achievement and collaborative research in translational medicine. Limits of the cooperation model will be highlighted and conflict resolution theory will be harnessed to propose a framework where investigators can go beyond cooperation to reach greater achievement in research.

Objectives
1. Highlight the tension between individual and team based achievement inherent in the current hyper-competitive biomedical research context.
2. Identify differences in approaching collaborative research with different organizations (academia versus industry).
3. Understand the limits of the conventional model of cooperation.
4. Explore the use of conflict resolution theory as a framework to go beyond competition and increase collaboration for meaningful research achievement.
5. Identify strategies to tackle obstacles in collaborative research.

Wednesday Social Program
18:30 Wine and Cheese @ Barcollo
Thursday, April 27th

**Coffee**
Time: 8:15 - 8:30

**Debriefing**
Facilitator: Janet P. Hafler
Time: 8:30 - 9:00

**Cross-pollinate and Feedforward**
Facilitator: Salmaan Sana
Time: 9:00 - 11:15
See "Team Building and Social Impact" page on 22 for overview

**Post Market Analysis**
Presenter: Martin Offringa and Nancy Sweitzer
Time: 11:15 - 12:30

**Abstract**
Developing a new medical product today not only means getting an approval from a regulatory agency. Increasingly the action for successful marketing of new medical products has shifted to the world post-approval. We will explore what the post-market world means for successfully bringing a new product to patients and for continuing to monitor how well the product works in real world medical practices. We will also discuss new models of approval that incorporate more real world post-market research into an evolving approval process.

**Group Lunch, 12:30 - 13:45**

**Science 3.0**
Presenter: Frank Miedema
Time: 13:45 - 14:30

**Abstract**
When people think of a scientist, they often think of someone who has his or her head in the clouds, motivated by an entirely untainted desire for the pursuit of knowledge and truth. In this presentation, Frank Miedema will cast aside these beliefs about scientists as needlessly naive, and instead suggest that we rebuild our idea of the sciences, particularly the life sciences, with today’s economic reality in mind.

**Objectives**
1. Understand the impact of external forces on Science as it relates to translational Medicine
2. Develop awareness of the way science shapes both economic and social progress in modern society
3. Realize how increasing pressure to solve real-world problems has forced scientists out of the ivory tower and into the corporate world.

**Unfolding Case Study 3 - The Magic Bullet (continued)**
Written by: Vicki Seyfert-Margolis
Time: 14:30 - 15:30

**Keynote Encounter II**
**Biotech Investing**
Presenter: George Rehm and Steve Myint
Time: 15:30 - 16:30

**Abstract**
Want to know what investors are looking for in an idea? In an entrepreneur? Two experienced investors will discuss how they think about new innovations – what they invest in and why. They will also tell us what they think are the new horizons for investing models. Is the traditional venture capitalist model a dinosaur?

**Break, 16:30 - 16:45**

**Speed Dating II**
Time: 16:45 - 18:15 (starts promptly at 16:45)

**Abstract and Objectives**
“Speed dating II” provides another opportunity for participants to have a series of one-on-one discussions with individual faculty for 10 minutes each. Topics are the participant’s choice. Please consult the faculty biographies at the end of this program prior to completing the signup sheet, which will be available which will be prominently displayed and made available from Sunday.

**Personal work time for Presentation Workshop II**
Time: 18:15 - 19:30
Friday, April 28th

**Coffee**
Time: 8:15 - 8:30

**Debriefing**
Facilitator: Janet P. Hafler
Time: 8:30 - 9:00

**Modeling diseases and therapies in experimental systems**
Presenters: Norman Rosenblum and Uri Tabori
Time: 09:00 - 10:00

**Abstract**
Animal models are commonly used to model human diseases. But how reliable are these models? How does the researcher decide? Participants will analyze dilemmas researchers can face while working with animal models.

**Objectives**
1. Discuss when and why to use animal models
2. Examine how to use animal models
3. Explore the differences between animal models and human diseases

**Break, 10:00 – 10:15**

“So You Want To Start a Company?”
Presenters: Wainwright Fishburn
Comments: George Rehm and Timothy Triche
Time: 10:15 - 11:45

**Abstract**
There are various considerations when considering starting a company; such as the vast expanse between an idea and its delivery to patients and the market. These are often cloaked by the fog of unawareness and swept by the winds of uncertainty. Many dangers lurk in it. We will discuss the various challenges which have to be overcome, including but not limited to funding in the current climate. We will suggest strategies to maximise the chances of success. Our objective is to disperse the fog and provide awareness of the process.

**Objectives**
1. Identify the elements leading to the formation of a company as a development vehicle for a translational idea
2. Describe the current funding process as well as funding policies and their impact
3. Examine the challenges start-ups encounter in developing an idea into a product tangibly benefitting patients

**Group Lunch, 11:45 – 13:15**

Siracusa

Some 2,700 years ago, one of the first Greek settlers dubbed this area “Sarako”. This was in reference to the surrounding salt marshes, beautiful areas dense with sensitive and highly specialized vegetation. Its strategic location and savvy inhabitants helped make Siracusa one of the most powerful city-states in all of Magna Grecia. Cicero called it “the most beautiful of them all”. Ruling factions have changed over time, with the Romans, Byzantines, Arabs, Normans and Swabians all fighting for supremacy in the region. Sicily (and Siracusa) has survived each invasion, and absorbed some important influences evident today. For example, May is the opening month of the Greek Theatre, a premier theatrical event in all of Italy. Architecture further infuses the bones of the city, doric and ionic, baroque and roccoco. And art (high and low, old and new) adorns the city-scape and enriches its museums. Siracusa is not buried in its past, however. The city’s heartbeat is strong with the song of the dolce vita; “ragazzi” enjoy the night life sitting at an open-air coffee-shops, or dancing in one of the many clubs that are concentrated in the area between Piazza Archimede, Piazza Duomo, the Aretusa Fountain and the Alfeo Promenade.
Friday, April 28th cont.

**Presentation Workshop II**
Facilitators: Norman Roseblum, Carol Gregorio, Janet P. Hafler, David Hafler, Berent Prakken, Nancy Swetzler, Lucy Wedderburn, Salvatore Albani, Alessia Fornoni, Kee Chong Ng, Rosalind Smyth and Carl Moons.
Time: 13:15 - 15:45

**Abstract**
Building on the skills developed in Presentation Workshop I and the curriculum on the nature of translational medicine, the presenter will may focus on an issue related to the translational medicine pathway that the presenter seeks to bring to an institutional leader in order to generate a change that will enhance translational medicine.

**Objectives**
1. Develop the best methods to deliver a persuasive method to an institutional leader to generate collaboration towards change.
2. Identify strengths and areas for improvement in your presentation approach.
3. Identify factors and strategies that will allow you to present more effectively to an institutional leader.

**Break, 15:45 – 16:00**

**Mentoring Session II**
Time: 16:00 - 18:30

**Abstract and Goals**
See session 1 (Sunday) for abstract and Goals.

---

**Sicilian Delicacies**

The title for the “Gastronomic Capital” of Italy is certainly a matter for debate. While some would claim it to be in the Northern regions of the country (specifically Bologna), the South is rich with fresh delicacies. As an island, it makes sense that fish would rank among these fine foods. Bluefin tuna is native of Sicilian waters and sought throughout the world, especially Japan. Fishing techniques date back well over a millennium, with some traceable to Arab rule, and others suspected to be vestiges from the Carthaginian period. Tonnarotti (Italian for tuna fisherman), might recommend a simple breaded tuna steak, while others could tout the finer qualities of “purpetti” (tuna croquettes), or “salsiccia di tonno” (tuna sausage), or even tuna stew. However, one cannot live on fish alone (arguably).

Arabic influences transcends savory dishes, and inspires the sweet. Honey, almonds, and sesame seeds are all linked with the Arabic era in Sicily. They are also the main ingredients for sweets in Siracusa. The “giuggiulena” is a perfect example. Giuggiulena is a hard candy made from exactly those three ingredients. Pistachios, ricotta cheese and chocolate also grace many recipes. Consider the “cassata siracusana” with ricotta cheese and chocolate, or perhaps save your calories for authentic and irreproducible Sicilian cannoli. Since we’ll be in Siracusa during the Santa Lucia festival, one might try a “cuccia”, made with ricotta cheese and candied squash and fruit. Granita (an icy concoction with almond milk) is paradise on a hot summer day.

After all this eating, you might be thirsty. One thing to try (aside from granita) is Nero d’Avola. The origin of the varietal is unknown, and has thus far only been found in Sicily. A sweeter palate will revel in the wine described by Homer and Hesiod: Moscato di Siracusa, which is rumored to be oldest wine in Italy.
Saturday, April 29th

Coffee
Time: 8:15 - 8:30

Debriefing
Facilitator: Janet P. Hafler
Time: 8:30 - 9:00

Citizen Science: Publications for “real” people
Presenters: Berent Prakken, David Hafler and Vicki Seyfert-Margolis
Time: 09:00 - 10:00

Abstract
As science and technology touch every aspect of peoples’ lives, we as scientists are having an ever more profound impact on our society. And much of our work is sponsored by the public. Yet we often don’t think about our responsibility to engage our communities and societies outside of our peers. What is our social contract with the people who fund us and who we serve?

Break, 10:00 – 10:15

A Most Compelling Presentation
Facilitator: Salmaan Sana
Time: 10:15 - 12:15
see the “Team Building and Social Impact” page on 22 for overview

Group Lunch, 12:15 – 13:30

Plenary Session based on Unfolding Cases
Presenters: Norman Rosenblum and Vicki Seyfert-Margolis with all faculty
Time: 13:30 - 15:00

Free Afternoon

Saturday Social Program
20:00 closing dinner

After a week of hard work, creativity and fun please join us for an amazing dinner with enticing wines. Dinner will be served at Ristorante Don Camillo (Via delle Maestranze, 96). It is located at the historical city center of Siracusa and set in the beautiful Catalan vaults.
Team Building and Social Impact

Program Coordinators: Salmaan Sana and Anita Small
Program Facilitator: Salmaan Sana
Process Consultant: Anita Small
Local Dream Team: Roberto Risicato, Giovanni Licciardello, Valeria Drago and Manuela Battagia
Faculty Team Facilitators: Berent Prakken, Norman Rosenblum, Salvatore Albani, Vicky Seyfert-Margolis, Martin Offringa and Carol Gregorio

Abstract
A goal of our program is to address developing collaborative skills that may be applied to a local social impact project in translational medicine. This activity provides the opportunity to work with local health care professionals in teams to address translational medicine concerns and to reflect on group processes.

In this particular part of the program, you will learn how to work and lead collaboratively and more efficiently as a team and develop your personal skills within groups to translate your learning into meaningful practice. It simultaneously focuses on encouraging you to realize your potential impact. You will work in teams and find ways of utilizing your talents as well as supporting others in using theirs. Becoming aware of your role on a team is directly related to the potential impact you and your team can have within this part of the program.

The four sessions are broken up into the following themes:
Connect Before You Lead (Sunday)
Let Us Get Working (Monday)
Cross-pollinate and Feedforward (Thursday)
A Most Compelling Presentation (Saturday)

Objectives
1. Refine your teamwork skills.
2. Develop skills to work collaboratively in interdisciplinary teams within a translational medicine context.
3. Learn about the social determinants of health and how they translate to a local setting.
4. Develop research questions that a local team of healthcare professionals can use to build on further.
Eureka Translational Creativity

In 2011, the time was ripe for the Eureka Institute for Translational Medicine to add art into its program: Eureka Translational Creativity was born. Translational Creativity was developed to complement Eureka’s education and community building initiatives.

Anna van Suchtelen and Brian Goeltzenleuchter are internationally respected artists who have a long history of collaboration. Their Eureka workshop When to Throw a Painting to a Drowning Man highlights the false dilemma of considering art and science as binary opposites. Focusing instead on the commonality of innovation, the artists produced curriculum for science innovators who strive to come to terms with the uncertainty that comes with working collaboratively and across disciplinary borders.

The core theme of the workshop is that creativity is not a talent that one either has or does not have: rather, it is a tool that can be activated and deactivated. Through participating in hands-on and often laughter-inducing group activities, students learn when, why, and how creativity can be deployed in their professional lives.

Translational Creativity CV

2011 – Artists-in-Residence: Brian Goeltzenleuchter and Anna van Suchtelen
2012 – Film release: When to Throw a Painting to a Drowning Man
2013 – Artist-in-Residence: Kate Breakey; Artwork: The Syracuse Still Life
2014 – Artists-in-Residence: Brian Goeltzenleuchter and Anna van Suchtelen; Workshop: When to Throw a Painting to a Drowning Man, Artwork: Paintings for Drowning Men Artists’ Multiple
2015 – Artists-in-Residence: Brian Goeltzenleuchter and Anna van Suchtelen; Workshop: When to Throw a Painting to a Drowning Man, Artwork: Paintings for Drowning Men Hardbound Folio

On the film

When to Throw a Painting to a Drowning Man is an artist-made self-help video that shows how creativity can be useful to anyone. The video offers parables and exercises that evoke the structure of a self-help book. It celebrates the transcendent nature of creativity, examining its potential as a skill and tool for problem solving, critical thinking, networking, and team building. (http://vimeo.com/47049893)
ADMINISTRATIVE FACULTY BIOGRAPHY

Julia Ong, BCOM

Julia has over 27 years of vast experience as an administrator and of which, 15 years were in healthcare. Julia joined KK Women’s and Children’s Hospital in the year 2006 and has been involved with setting up numerous initiatives in the hospital; the Women Mental Wellness Service in 2006-2011, SingHealth Duke-NUS Paediatrics Academic Clinical Programme in 2012-2016 and the initial set up of Professor Albani’s SingHealth Translational Immunology and Inflammation Centre in 2013.

Julia joins Eureka Institute from October 2013. Since February 2016, she was seconded to run Eureka Institute. This is the four year she is coordinating the Eureka certificate program.
FACULTY DISCLOSURES

Nothing to disclose
Salvatore Albani, MD, PhD
Patricia Furlong, RN, BS, MS
Valeria Drago MD, PhD
Brian Goeltzenleuchter, Artists-in-Residence
Janet Hafler, EdD
Patrick Maxwell, FMedSci
Frank Miedema, PhD
Steven Myint, MD, PhD
Martin Offringa, MD, PhD
Maria Grazia Roncarolo, MD

Norman Rosenblum, MD FRCP
Vicki Seyfert-Margolis, PhD
Anna van Schtelen, Artists-in-Residence
Timothy Triche, MD, PhD
Thorsten Vetter, MD
Lucy Wedderburn, MD, FRCP, PhD

Disclosures
Manuela Battagia, PhD,
discloses an affiliation with EU, JDRF, Fondazione Cariplo for
grant/research support and as a consultant to TrialNet.

Wainwright Fishburn, JD,
discloses an affiliation as a partner at Cooley LLP which rep-resents over 650 life science companies.

Carol Gregorio, PhD,
discloses an affiliation with NIH for grant/research support.

David Hafler, MD,
discloses an affiliation with Biohaven Pharma (dba PharmaHaven),
Bristol-Myers Squibb, EMD Serono, Genentech (a member of the Roche group), MedImmune (a member of AstraZeneca), Merck Sharp & Dohme, NeuroPhage Pharma (became Proclara Biosciences), No-vartis Pharmaceuticals and Sanofi Genzyme as a consultant/Scientific Advisory Board.

Berent Prakken, MD, PhD,
discloses an affiliation with Dutch Arthritis Foundation for grant/research support.

Sergio Quezada, PhD,
discloses an affiliation with TUSK Therapeutics for grant/research support and as a consultant to TUSK Therapeutics, Achilles Therapeutics and Morphosys.

George Rehm, JD,
discloses an affiliation as a consultant to Genome Dx, My Own Med, Jiff Solstice Bio, Patient Wisdom TT tech AG, Butterfly Networks, LAM Therapeutics, Qsi, Hyperfine Research, 4Catalyzer, and a major stock shareholder of EVP GmbH & Co KG.

Salmaan Sana,
discloses an affiliation as a consultant to Better Future.

Anita Small, MS, EdD,
discloses an affiliation as a consultant to the Royal Ontario Mu-seum, Theatre Passe Muraille, Opera Atelier, Cahoots Theatre, Deaf Culture Centre, H3TV, Ontario Arts Council, Canada Council for the Arts, Alliance of Canadian Cinema, Television and Radio Artists and Professional Association of Canadian Theatres.

Uri Tabori, MD,
discloses an affiliation as a recipient of the Stand UP to Cancer and the American Academy of Cancer Research Catalyst grant which has partial funding from BMS.

Nancy Sweiter, MD, PhD,
discloses an affiliation with Novartis, Merck, AHA and NIH for grant/research support, and as a consultant to Medtronic and Acorda.

Disclosure not available at time of printing:
Giovanni Lucciardello, MD
Roberto Risicato, MD
Salvatore Albani, MD, PhD, is an internationally renowned rheumatologist and immunologist. He is currently Professor of Medicine at Duke-NUS Medical School in Singapore, and the Director of the Translational Immunology Centre at SingHealth/Duke. Before joining Duke-NUS, Dr. Albani served as director of the Translational Medicine Unit at the Clinical Investigation Institute at the University of California, San Diego, where he also was professor of Medicine and Pediatrics. His fundamental research interest is in understanding human immunity and contributing the knowledge to therapeutic and diagnostic advancements. He has developed several innovative approaches in the area of induction and maintenance of immune tolerance in humans, being responsible for the whole translational process from idea to the conclusion of a Phase II clinical trial in autoimmune inflammatory diseases, which have a large impact on society and individuals. He has been responsible for conception and execution of each of the stages of this complex itinerary, which spans a wide and diverse gradient of technologies and challenges.

These include molecular immunology, lead identification and validation, intellectual property, CMC (Chemistry, Manufacturing and Controls), IND (Investigational New Drug filings), trial design, data management and analysis, interfacing with Venture Capital and Pharma, leading complex groups in a multi-center setting, etc. The technology platform has applications in diseases that could benefit from a restoration of immune tolerance. This translational research itinerary has been the original backbone of my career, as witnessed by a rich publication trail (among others Nature Medicine, Lancet, JCI, PNAS, Nature Rheumatology, A&R, ARD, etc, H factor 34) and by approximately 100 patents. Development of high throughput technology platforms is also part of his scientific career. These platforms aim to provide tools for knowledge-based diagnostic and therapeutic decisions.

In his role as an educator, it has been his privilege to mentor many talented individuals, and to provide the right challenges and learning opportunities to help them grow and advance. He seeks to expand this even further by helping to create and nurture the next generation of translational scientists. An important step is cultivating in translational professionals the necessary awareness, knowledge and experience to contribute significantly to the advancement of the field.

"My professional mission is to build bridges between unmet medical needs and Translational Sciences."
Manuela Battaglia is the Vice Director of the San Raffaele Diabetes Research Institute in Milan, Italy. She received her PhD from the Medical College of Wisconsin in 2001, and eventually returned to Italy as a post-doctoral fellow at the San Raffaele Telethon Institute for Gene Therapy in Milan under the direct supervision of Prof. Maria Grazia Roncarolo. After six years of intensive work in the field of gene therapy, Manuela decided to invest her scientific career in understanding, and possibly finding a definitive solution for, type 1 diabetes. Thus, in 2007 she moved to the San Raffaele Diabetes Research Institute (Milan, Italy) as a group leader, and she was subsequently promoted head of unit (2012). Fascinated by human immunology, and deeply committed to research in this sphere, she believes that access to - and the subsequent study of - precious human samples is key to the advancement of biomedical knowledge. At the same time, she recognizes the power of animal models, and makes constant use of them.

Manuela is one of the member of the Steering Committee of TrialNet (an NIH-founded international network of researchers who are exploring ways to prevent, delay and reverse the progression of type 1 diabetes). Manuela's over-riding target is to understand how the immune system transforms during autoimmunity and how said system can be manipulated to prevent/block immune-mediated diseases (such as graft rejection). She supervises science on the bench, but her mind's eyes hovers constantly at the bed-side and ponders how to improve patient benefits. She is currently developing a phase I/II study with T-regulatory-cell therapy after solid organ transplantation.

Her main goal in Science (and in Life) is to work hard to continuously challenge and (possibly) overcome "dogmas".
Dr Drago is an MD, PhD graduated cum laude at University of Messina, Italy. In the same institution she has done her internship in Internal Medicine and her Residency in Neurology. Since the beginning of her graduate education she maintained active involvement in conducting research. Her clinical and research interests evolved as she won a scholarship to serve as a physician in training at the S. Jose do Rio Preto Hospital, Brasil (1997) and the following year at the TelAviv Hospital, Israel (1998). In April 2004 she began her fellowship training at University of Florida (Gainesville, FL, USA) where she completed a three years fellowship in Cognitive and Behavioral Neurology. After the fellowship she got an appointment as an Adjunct Assistant Professor and kept working in Gainesville until July 2009. She held a courtesy appointment through the Department of Neurology at UF until 2015. She graduated as a PhD in sleep medicine at University of Bologna and worked as a research neurologist at IRCCS in Brescia from 2010 to 2012. Many of the projects she conducted are focused on mechanisms of attention and neglect in normal subjects and patients affected by cerebrovascular disease and on cognitive and memory deficits associated with Alzheimer’s and Parkinson's diseases, as well as Frontal lobe’s functions and creativity. She published about 65 scientific papers, all of them are published in peer reviewed international scientific journals, she authored and coauthored several invited chapters and serves as an ad hoc reviewers for several neurology and neuropsychology journals. From 2012 she has a full time clinical track position as an Attending Neurologist at “Muscatello Hospital” in Augusta Syracuse.
Wainwright Fishburn, JD

"As a recognized life science and digital health thought-leader, Wain is a frequent speaker at programs addressing industry issues..."

Wainwright Fishburn, Jr. is a founding partner of Cooley LLP’s San Diego office, a prominent venture capital attorney and chair of the firm’s Digital Health group.

As a recognized life science and digital health thought-leader, Wain is a frequent speaker at programs addressing industry issues, including at the International CES Digital Health Summit, USC’s Body Computing Conference, Impact Forum and the Samsung: Health + Tech Conference. Wain has also served as the Chair of the BIO Digital Health Forum at the BIO International Convention from 2014 – 2017.

As both a founder and counsel, Wain has worked with venture capital-backed companies across a variety of fields. For example, in the field of genomic medicine, he works with groups that develop and deploy high-performance network technology for genomic research and medicine. He is Vice-Chairman of the Board of the Critical Path Institute, a public-private partnership created in part by the FDA, dedicated to integrating scientific advances into the development pathway. Mr. Fishburn has been widely recognized as a leading attorney in numerous publications, including among others, his recognition by The Daily Journal as one of California’s top attorneys. He was named by Nature as instrumental to the success of San Diego as a life science cluster.

As a community leader, Wain is a member of the Executive Committee and past Chairman of the Sanford Burnham Prebys Medical Discovery Institute, one of the nation’s leading independent biomedical research institutes. He recently joined the Executive Committee of the Board of the UCSD Moores Cancer Center where he is afforded a clinical perspective for the application of breakthroughs in genomic medicine and is assisting with the Center for Personalized Cancer Therapy. He is a founding director of both the Corporate Directors Forum and BIOCOM, the largest regional life science association in the world, representing more than 860 member companies and is a member of its Executive Committee.

Wain is a co-founder of seven companies, two of which are public. He is a third-generation Arizonian and earned his B.A. from the University of Arizona. He completed post-graduate work as a Senior Fellow at the Australian National University and received his JD degree from the University of California, Hastings College of the Law where he served as President of the Hastings Board of Governors.
Pat Furlong is the Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest nonprofit organization in the United States solely focused on Duchenne muscular dystrophy (Duchenne). Their mission is to end Duchenne. They accelerate research, raise their voices in Washington, demand optimal care for all young men, and educate the global community.

Duchenne is the most common fatal, genetic childhood disorder, which affects approximately 1 out of every 3,500 boys each year worldwide. It currently has no cure.

When doctors diagnosed her two sons, Christopher and Patrick, with Duchenne in 1984, Pat didn’t accept “there’s no hope and little help” as an answer. Pat immersed herself in Duchenne, working to understand the pathology of the disorder, the extent of research investment and the mechanisms for optimal care. Her sons lost their battle with Duchenne in their teenage years, but she continues to fight—in their honor and for all families affected by Duchenne.

In 1994, Pat, together with other parents of young men with Duchenne, founded PPMD to change the course of Duchenne and, ultimately, to find a cure. Today, Pat continues to lead the organization and is considered one of the foremost authorities on Duchenne in the world.
Brian Goeltzenleuchter (b. 1976) is an artist based in San Diego, USA. His recent projects investigate the use-value of cultural objects and institutions. In 2001 Goeltzenleuchter received his MFA from the University of California, San Diego. From 2002 - 2008 he was Associate Professor of Art at Central Washington University. He is currently a Research Fellow at the Institute for Public and Urban Affairs at San Diego State University, and Artist-In-Residence at the Institute for Art and Olfaction in Los Angeles. His work has been screened, performed, and exhibited throughout the United States, Canada, Austria, Italy, China, Croatia, and the Netherlands. Selected projects include: Sillage, Santa Monica Museum of Art (2014); Adaptive Equipment, Lust Gallery, Vienna, Austria (2011); c (pronounced /k/) Wellness Centre, Southern Alberta Art Gallery, Canada (2010); c Boutique, Museum of Contemporary Art, San Diego (2010); Sponge X Sponge, Colorado State University (2007); Institutional Wellbeing, Centrum Beeldende Kunst, The Netherlands (2006); Who’s not for sale, Banff Centre, Canada (2006); Unpacking Iraq, International Festival of New Film/New Media Split, Croatia (2004)
Carol Gregorio, PhD

"Dr. Gregorio is the Vice-Dean for Innovation and Development at the University of Arizona."

Dr. Gregorio is the Vice-Dean for Innovation and Development at the University of Arizona. She also built and currently directs the Sarver Molecular Cardiovascular Research Program (MCRP) at the University of Arizona. Researchers in the MCRP are focused on discovering and disseminating knowledge about the underlying biological and molecular mechanisms of heart development, heart function, heart disease and other malfunctions of the cardiovascular system. Their efforts emphasize translational research. She is also the head of a medical school academic department whose primary missions are to decipher the primary cause of human disease and to train the next generation of Translational Scientists. Dr. Gregorio herself runs an active and well-funded research program with a focus broadly summarized as understanding the cellular mechanisms involved in the assembly, regulation and maintenance of contractile proteins in cardiac and skeletal muscle in health and disease. Dr. Gregorio is an active member of several editorial and philanthropic boards, and is a frequent grant reviewer at the National Institutes of Health. She received her Doctorate from Roswell Park Cancer Institute in Buffalo, NY with a major in Molecular Immunology, and did her postdoctoral fellowship at the Scripps Research Institute in La Jolla, CA.
Dr. Hafler is the William S. and Lois Stiles Edgerly Professor and Chairman Department of Neurology and Professor of Immunobiology, Yale School of Medicine, and is the Neurologist-in-Chief of the Yale-New Haven Hospital. He graduated magna cum laude in 1974 from Emory University with combined BS and MSc. degrees in biochemistry, and the University of Miami School of Medicine in 1978. He then completed his internship in internal medicine at Johns Hopkins followed by a neurology residency at Cornell Medical Center-New York Hospital in New York. Dr. Hafler was trained in immunology at the Rockefeller University and then at Harvard where he joined the faculty in 1984 and later became the Breakstone Professorship of Neurology at Harvard and was a founding Associated Member of the Board Institute at MIT. In 2009 he move to Yale as the Chair of the Department of Neurology. Dr. Hafler is a clinical scientist with a research interest in the mechanism of multiple sclerosis with over 370 publications in the field of MS, autoimmunity and immunology. He is a co-founder of the International MS Genetic Consortium a group that identified the genes causing MS. Dr. Hafler has been elected to membership in the American Society of Clinical Investigation, the Alpha Omega Society, and was a Weaver Scholar of the NMSS. He is a member of the editorial boards for Journal of Clinical Investigation and the Journal of Experimental Medicine, and is co-founder of the Federation of Clinical Investigation and the Journal of Experimental Medicine, and is co-founder of the Federation of Clinical Immunology Societies and leads the NIH Autoimmunity Prevention Center Grant at Yale. Hafler was a Jacob Javits Merit Award Recipient from the NIH and has won many awards including 2010 Dystel Prize for MS research from the American Academy of Neurology.
Janet Hafler is a Professor of Pediatrics and is the Associate Dean for Educational Scholarship at Yale University School of Medicine. As the Director of the Teaching and Learning Center her responsibilities include developing and implementing medical education and teaching and learning programs for faculty members, students and residents. Over her career she has nurtured a climate in teaching and learning where faculty and residents have been exposed to the cutting edge literature and ideas in medical education. She has focused on assisting faculty and residents in exploring innovative ways to effectively promote learning in both the classroom and clinical settings.

Promoting, influencing and nurturing a climate in which physicians, residents and students can teach — and learn — has been foremost among her career objectives. She has focused on providing an awareness of context for students, residents and faculty, urging them to be innovative in their many teaching environments and encouraging them to explore ways to understand how they can effectively promote learning in their interactions among themselves.

Dr. Hafler runs an active research program applying qualitative research methods in medical education. She collaborates with and mentors clinicians and faculty on the elements of qualitative research in the field of medical education and medical care. In turn, mentored faculty members have learned to develop and demonstrate the tools necessary to effectively teach and lead others. Dr. Hafler has published over 100 book chapters, curriculum materials and original articles in medical education and clinical journals. She has served as visiting professor internationally and has been invited to present regularly at regional and national professional meetings.

From 1988 resident physician cardiologist and later physician assistant, medical manager in the division of Cardiology department Ferrarotto hospital University of Catania. From 2000 chief of CCU at the same department; from 2012 full director of Cardiology Department at Muscatello Hospital Augusta SR.

Member of the Italian Association of Cardiology, of the Italian Society of Arrhythmia and Cardiac Stimulation, of the Italian Society of Cardiology and European Society of Cardiology. Actually President of Sicilian District of Italian association of Cardiac Pacing and Electrophysiology.

He has participated to numerous clinical and scientifical researches and relevant clinical, pharmacological and interventional trials as principal and co-investigator. He has got post doctoral and fellowship training in Electrophysiology, Cardiac Pacing and Catheter Ablation of Cardiac Arrhythmia at the Cardiological Department of Asti Hospital (University of Turin).

He has participated as speaker moderator, discussant to numerous update national and international meetings on cardiovascular medicine and clinical and interventional issue arrhythmology.

He published about 55 scientific papers as author and co-author in peer reviewed national interventional scientific journals.

Contract professor at the Graduate Cardiology School of Catania University for supplementary courses on “Approach to critical patient in CCU and invasive investigation of electrophysiology for preexitation syndrome and diagnosis of ischemic heart disease”. In 2006 he got a post-graduated course in Public Health and management organisation as responsible for complex sanitary institution. He experienced more than 4000 cases of cardiac pacemaker icd and crt implantation and electrophysiological study and catheter ablation of principal cardiac arrhythmia as principal operator.
Professor Patrick Maxwell is currently Regius Professor of Physic at the University of Cambridge.

He graduated from Corpus Christi College, Oxford, in 1983 with First Class Honours in Physiological Sciences. Subsequently, he did his clinical training at St Thomas’ Hospital where he won the Mead Medal in Medicine and the Cheselden Medal in Surgery. The principal thrust of his research is in transcriptional control of genes by oxygen. He has worked on this for more than twenty years, initially in Oxford and then as Professor of Nephrology at Imperial College before moving to UCL in 2008 as Professor of Medicine and then Dean of Medical Sciences. His research programme has received substantial national and international recognition and has considerable potential for translation into new therapies for patients. In 2003 with three other scientists, he set up ReOx, an Oxford University spin-out company which ultimately aims to develop medicines from these discoveries.

Professor Maxwell is a Fellow of the Royal College of Physicians, Fellow of the Academy of Medical Sciences and a Fellow of Trinity College Cambridge.

The Regius Professor of Physic is Head of the School of Clinical Medicine at the University of Cambridge and Executive Director of Cambridge University Health Partners, the Academic Health Sciences Centre for Cambridge.
Frank Miedema (1954) studied biochemistry at the University of Groningen, specializing in immunology, with a minor in Philosophy of Science. He obtained a PhD from the University of Amsterdam at the Central Laboratory of the Blood Transfusion Service (CLB), now Sanquin. There, from 1983 he was project leader immunovirology of HIV/AIDS as part of the Amsterdam Cohort Studies. In 1996 he was appointed full professor at AMC/University of Amsterdam and in became Director of Sanquin Research in 1998. In 2004 he became head of the Immunology department at the University Medical Center Utrecht. From 2009 he is dean and vice chairman of the Executive Board at the University Medical Center Utrecht.

He is one of the initiators of www.scienceintransition.nl/english. Science in Transition believes that the scientific incentive and reward system is in need of fundamental reform. Next to Science for Science (articles in journals), the added value for society needs to be more appreciation and societal stakeholders should be involved more integrally in the production of knowledge.
Prof Steven Myint is a physician with global experience in health and biomedical management. He is currently a Senior fellow to A*STAR, and consultant to its commercialization arm, ETPL. He is also Adjunct Professor at Duke-NUS in the Center for Technology, Enterprise and Development. In these capacities he is involved in the commercialization of biomedical and bio-engineering research.

He is also Chairman of Inex Private Ltd. In Finland he is chairman of Plexpress Oy and Inc, a diagnostic technology company with a US subsidiary and non-executive director of Aplagon Oy and Primex Oy, both biotech companies. He was also founding partner of a Finnish Vigo accelerator, Ukko Partners. In addition he is a partner in the Palo Alto based venture fund, Pharma Capital and a non-executive director of Lipid Genomics, a diagnostic company spun out of Johns Hopkins, now based in Boston. Until recently he was also executive chairman of Green Signal Bio, which he developed into one of India’s largest vaccine manufacturers. He has held non-executive directorships with several organisations in the public and private sectors. He is a former Professor and Dean of Medicine & Health at the University of Surrey and Professor/Chairman of Microbiology & Immunology at the University of Leicester in the UK. He has been a biopharmaceutical senior and Board executive as global Medical Director at GlaxoSmithKline and Senior Vice-President for R&D/Chief Medical Officer at BTG International. He has been instrumental in over 50 successful IND and 12 NDA submissions. He was an NHS consultant in UK for over 20 years and is also a former Senior Independent Director, then chairman, of a hospital in the NHS and Board Member of Care International.

He also has experience in the IT sector as executive chairman of Onmedica Group Ltd and Onmedica India Private Ltd (a health/IT and marketing organization). He has also been Chief Executive of the European Federation of Neurological Associations, consultant to several organisations in the medical and financial worlds and member of several national and international advisory boards. He has authored over 120 peer reviewed publications and 6 books. He was also Editor-in-Chief of the Journal of Infection for 5 years. He is a Fellow or Member of several societies, including the Institute of Knowledge Transfer, the Royal College of Physicians and the Royal Society of Medicine. After his own first university spinout in 2005, he has been involved in the development of over 30 SME’s in life sciences and created over $1billion value for shareholders.
Martin Offringa, MD, PhD

"Dr. Offringa is a staff physician in the Department of Paediatrics and the Division of Neonatology and Professor at the University of Toronto’s Institute of Health Policy, Management and Evaluation (iHPME)."

Dr. Offringa is a staff physician in the Department of Paediatrics and the Division of Neonatology and Professor at the University of Toronto’s Institute of Health Policy, Management and Evaluation (iHPME). He is Senior Scientist and Head of the Child Health Evaluative Sciences Program in the Hospital for Sick Children’s Research Institute. Trained in Amsterdam, Rotterdam and at Tufts University in Boston, he is also Professor of Clinical Epidemiology at the University of Amsterdam, Co-Director of the Dutch National Paediatric Pharmacotherapy Expertise Network (NKFK) and founding Director of the Medicines for Children Research Network (MCRN) in the Netherlands; the Dutch Ministry of Health funded both networks. Since 2009, he has chaired the steering group of StaR Child Health, an international initiative that aims to enhance the design, conduct and reporting of clinical trials in children. His contributions to the development, validation and harmonization of innovative research tools have identified and subsequently filled important gaps in current research methods. He currently leads a Canadian Institutes of Health Research funded research group that will develop, validate and implement a new outcome-reporting standard: Instrument for reporting of Planned Endpoints in CTs (InsPECT). This instrument will be validated in trials in neonatology, paediatric surgery, adolescent mental health and hip fractures in the elderly.
Berent Prakken (MD, PhD) is a professor of immunology and pediatrics at the Utrecht Medical Center Utrecht, the Netherlands. He is chair of Research and Education of the Wilhelmina Children’s Hospital. Berent Prakken heads a translational research lab that focuses on regulation of inflammation and biomarker development in human inflammatory diseases. He and his group received various prestigious national and international awards and grants. The Prakken lab hosted a core facility for the Immune Tolerance Network of the NIH, and is an international expertise centre for the Luminex technology. Prakken serves as an editor and associate editor of several journals including the Annals of Rheumatic Diseases and the European Journal of Immunology, and is a regular reviewer for most major journals in his field. Berent Prakken was among others chair of the standing committee of pediatric rheumatology in EULAR, and member of the PRES council and EULAR executive committee. He is member of the steering committee of UCAN (international federation facilitating biological research in arthritis) and (thanks to a 1 million euro grant from the Dutch Arthritis founda-tion) set up the first international platform for biological studies in arthritis (UCAN-U, www.ucan-u.org). He is coordinator of EUTRAIN, an EU FP7 Marie Curie Integrated Training Network for translational research in pediatric rheumatology. Berent Prakken’s personal commitment is to collaboration and training & education. Unconventional thinking and crossing traditional boundaries inspire him, just as his close friendship with Salvo Albani and the other board members of Eureka. As co-founder and board member he enjoys the journey on which Eureka is taking them.

"He is chair of Research and Education of the Wilhelmina Children's Hospital..."
Sergio Quezada, PhD

"Dr. Sergio Quezada is a Professorial Research Fellow and Group Leader at UCL Cancer Institute in London...."

Dr. Sergio Quezada is a Professorial Research Fellow and Group Leader at UCL Cancer Institute in London where he heads the Immune Regulation and Tumour Immunotherapy Laboratory. Prior to this, Dr. Quezada worked with Dr. James Allison at Memorial Sloan-Kettering Cancer Center studying the mechanisms governing anti-tumour T-cell immunity, and how these mechanisms can be manipulated for the generation of potent anti-tumour immune responses.

Dr. Quezada's research interest at UCL focuses in the study of the mechanism of action of anti-CTLA-4, anti-PD-1 and other immune-modulatory antibodies targeting co-inhibitory and co-stimulatory pathways (including ICOS, 4-1BB, OX-40) and used as novel anticancer therapies. His group has particular interest in the evolution of the immune response to cancer, the impact of immune-modulatory antibodies in the fate and function of tumour reactive T cells, and the role that the tumour microenvironment plays in the response and resistance to such therapies.

Dr. Quezada is a Cancer Research UK Career Development fellow and the recipient of a Cancer Research Institute investigator Award.
George Rehm is a founding partner of aeris CAPITAL AG. He joined aeris in 2004 and has over thirty years of experience as a lawyer and executive in international licensing, technology transfer and investment and privatization transactions in the US, Europe and Asia. He has held board or observer positions in numerous transformational healthcare companies, including Crescendo Biosciences, Adamas Pharmaceuticals, Ion Torrent, Inc. Currently, from a base in Northern California, he serves as a director of GenomeDx Inc., PFS Genetics, Butterfly Networks, LAM Therapeutics Inc., Solstice Biosciences and Jiff Inc as well as advising MyOwnMed, Patient Wisdom and emPower. He is also a board member of the Center for Gender and Refugee Studies, at UC Hastings College of Law. Prior to joining aeris, Mr. Rehm worked as legal counsel for numerous international technology transfer transactions and served as chief European consultant to Bristol-Myers Squibb on an oncology care project, which involved delivery of services through ambulatory clinics throughout the EU, after establishing law offices in the former Eastern Germany, the Czech Republic and Russia on behalf of US and German law firms. He received his BSFS from Georgetown University, and a JD from the University of California, Hastings College of Law in parallel to graduate studies in City Planning at the College of Environmental Design, UC Berkeley and served as graduate assistant at the Earl Warren Legal Institute, UC Berkeley, Boalt Hall. Mr. Rehm has written and lectured frequently in Germany and the US on international trade, investment, technology transfer, health care, and venture capital and is fluent in both German and English.
Risicato Roberto, MD

Director of Internal Medicine Unit with Unit of Neurology and Unit of Emergency, at Augusta (SR) Hospital
Major Field of interest Clinical Governance - Complexity in chronic diseases, comorbidity, chronic care model and continuity of care - Clinical Nutrition – IBD – Cirrhosis - COPD - Hearth Failure – Ultrasonography
Scientific Society partner FADOI fellowship and member of Training and updating Department of FADOI – National Coordinator of Nutrition Clinic Area of FADOI – Charter member, on 2007, of Eureka International Institute EUREKA for development of Translational Medicine
Maria Grazia Roncarolo, MD, is a Professor of Pediatrics and Medicine at Stanford School of Medicine, Chief of the Division of Pediatric Stem Cell Transplantation and Regenerative Medicine, Co-Director of the Bass Center for Childhood Blood Disease and Co-Director of the Institute for Stem Cell Biology and Regenerative Medicine.

Her efforts focus on the translation of scientific discoveries in genetic diseases and regenerative medicine into novel patient therapies, including treatments based on stem cells and gene therapy. Dr. Roncarolo, a pediatric immunologist by training, spent her early career in Lyon, France, where she focused on severe inherited metabolic and immune diseases, including severe combined immunodeficiency (SCID), better known as “bubble boy disease”.

Dr. Roncarolo was a key member of the first team to carry out stem cell transplants given before birth to treat these genetic diseases. Dr. Roncarolo then worked at the DNAX Research Institute for Molecular and Cellular Biology in Palo Alto, where she contributed to the discovery of novel cytokines, studying their role in the induction of tolerance and promotion of stem cell growth and differentiation. As director of the Telethon Institute for Cell and Gene Therapy at the San Raffaele Scientific Institute in Milan, Dr. Roncarolo successfully led the first stem cell-based gene therapy trial for SCID patients lacking adenosine deaminase (ADA), a severe life-threatening disorder. The trial, combining gene corrected blood stem cells with low-dose chemotherapy, is now considered the gold standard for gene therapy in inherited immune diseases. She was also the principal investigator in a successful gene therapy trial for Wiskott Aldrich Syndrome.

During her research on inherited immune diseases, Dr. Roncarolo also discovered a new class of T cells, called T regulatory type 1 cells. These cells play a key role in maintaining immune-system homeostasis by preventing autoimmune and inflammatory diseases and helping the immune system tolerate transplanted cells and organs. She recently discovered specific biomarkers for these T regulatory type 1 cells, which will be used to purify the cells for clinical use and for tracking in patients. She was the first to complete a successful clinical trial using T regulatory type 1 cells to prevent severe graft-versus-host disease in leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Dr. Roncarolo has brought many basic-science discoveries from the bench to patients in the field. She holds eight patents, with six more pending, for methods used in novel cell and gene therapies. She has published more than 280 scientific papers along with 22 book chapters, and her publications have been cited over 20,000 times. She is a Member of the Academia Europaea of Sciences and of the Austrian Academy of Sciences.
Dr. Norman Rosenblum is Professor of Pediatrics, Physiology, and Laboratory Medicine and Pathobiology at the University of Toronto, and a Pediatric Nephrologist and Senior Scientist in the Research Institute, the Hospital for Sick Children. He is the recipient of a Tier I Canada Research Chair in Developmental Nephrology. Dr. Rosenblum is a MD graduate of Dalhousie University. He completed a Pediatric residency and a fellowship in Pediatric Nephrology at the Children’s Hospital, Boston followed by a postdoctoral fellowship in the laboratory of Bjorn Olsen in the Department of Anatomy and Cell Biology, Harvard Medical School. Dr. Rosenblum was recruited in 1993 as a clinician scientist to the Hospital for Sick Children and University of Toronto. Since then, the focus of his research has been to elucidate molecular mechanisms that control normal and malformed kidney development in genetic mouse models with a focus on signaling by bone morphogenetic, WNT and Hedgehog proteins. His lab has generated several models of human kidney-urinary tract malformation. He has published over 110 peer-reviewed original manuscripts and book chapters.

Dr. Rosenblum is deeply engaged in developing and managing career development programs for clinician scientists. He founded and led the Canadian Child Health Clinician Scientist Program from 2001-2012. In his present role as Associate Dean, Physician Scientist Training in the Faculty of Medicine, University of Toronto, he is Director of both the MD/PhD and Clinician Investigator Programs. Dr. Rosenblum is immediate Past-President of the Canadian Society for Clinical Investigation and a current member of the Council of the American Pediatric Society. Norm is a founding member of the EUREKA Institute for Translational Medicine, a current member of its Executive and Board and Chair of the Certificate Course Program Committee.

Dr. Rosenblum is the recipient of the 2004 Aventis Pasteur Research Award, the American Pediatric Society inaugural 2006 Norman J. Siegel New Member Outstanding Science Award, the Society for Pediatric Research 2010 Maureen Andrew Award in Mentoring, and the Kidney Foundation of Canada 2011 Medal for Research Excellence.
Salmaan enjoys the irony of his last name being ‘Sana’, which also means ‘Health’ in Latin. His focus and speciality are in healthcare leadership, change and compassion. He is a creative program designer, facilitator and coach.

As coincidence would have it, he has a diverse background in healthcare: from being a very active medical student at the VUmc medical centre in Amsterdam, he initiated many projects on leadership and development of young doctors. In 2011 he started his foundation in human centred care called Compassion for Care which got a kick off after holding a TEDx talk in Maastricht in the very year he and his team started the movement. He was also a part of a team that ran leadership programmes for healthcare professionals, the healthcare leadership schools, which later on became the foundation “Humans of Health”. Salmaan was selected to be first ‘chief compassionate officer’ in a healthcare institute when this position was created. This gave him the insight and helped him realise what it takes to cultivate compassion in a healthcare institute. After having worked for his foundation, company and a series of different initiatives, he decided he wanted to have more impact with the work he does, which is when he was invited to join Better Future.

Currently, he is running programs in guiding resident educators in medical leadership. It is here where they learn how to both teach as well as be an example in medical leadership for their residents. For residents, he develops programs with the purpose of becoming a ‘Change agents’. With the current burn out rate being so high within healthcare professionals, Salmaan has been focusing on getting the very same professionals to have more influence on their work setting and turn down the dropout rate. He helps them develop their personal leadership and in all aspects of the word, become ‘healthy’ healthcare professionals.

At Better Future, Salmaan works very broadly with Healthcare institutes and faculties. He guides teams and organisations in becoming strategically purpose driven and getting the best out of everyone utilising intrinsic incentives and motivation. He enjoys enabling human potential and catalysing creativity. He works on ways of connecting social impact, personal leadership and team building.

On any other day, you can find him living in the South of Amsterdam, using his bike to get around the city, building some consistency in practising cross-fit, and dabbling in different kinds of writing.

For more information, go to his Linkedin profile www.linkedin.com/in/salmaansana
Vicki Seyfert-Margolis, PhD

"...founded My Own Med in January 2013, based on over two years of work on a database, web and mobile application platform technology for family based co-management of health."

Vicki Seyfert-Margolis, PhD founded My Own Med in January 2013, based on over two years of work on a database, web and mobile application platform technology for family based co-management of health. Previously, Dr. Seyfert-Margolis was the Senior Advisor for Science Innovation and Policy in the Office of the Commissioner of the US Food and Drug Administration. While at the FDA, she oversaw the development and execution of an agency wide strategic plan for regulatory science. Prior to the FDA, she served as Chief Scientific Officer at the Immune Tolerance Network (ITN), a non-profit consortium of researchers seeking new treatments for diseases of the immune system. At ITN, Dr. Seyfert-Margolis oversaw the development of over 20 leading edge assay development and centralized laboratory facilities, bringing them to GLP and CLIA compliance. She designed and implemented biomarker discovery studies for over 25 Phase II clinical trials across a broad array of immunologically mediated diseases including autoimmune disorders, allergy, and solid organ transplantation. Prior to this, she served as Director of the Office of Innovative Scientific Research Technologies at the National Institute of Allergy and Infectious Diseases at NIH, where she worked to integrate emerging technologies into existing immunology and infectious disease programs. Dr. Seyfert-Margolis completed her PhD in immunology at the University of Pennsylvania’s School of Medicine, and her post-doctoral fellowship work at Harvard University and the National Cancer Institute.
Anita Small, MSc, EdD

Founder/Owner
small LANGUAGE CONNECTIONS

Dr. Anita Small is a sociolinguist, educator and researcher. She is inspired to bridge seemingly different worlds through communication, language and culture. Dr. Small is founder and owner of small LANGUAGE CONNECTIONS, providing language, culture and communication consultation to non-profit organizations, theatres, museums, broadcast companies, businesses, educational institutions, artists and leaders. Her work focuses on giving “voice” to marginalized groups and creating collaborative communicative contexts for change. She is most known for her innovative program development in the Deaf community. She is Co-Founder and past Co-Director of the DEAF CULTURE CENTRE, Canada, the first of its kind internationally, featuring a museum, art gallery, library, archives and multi-media production studio. Dr. Small taught in the Deaf Education Training Program, Faculty of Education, York University for 12 years and in the Linguistics Department, University of Toronto. She is cross-appointed to Hogeschool Utrecht University, Institute for Sign Language & Deaf Studies, Netherlands researching Deaf performing arts. She has authored publications on language planning, bilingual pedagogy, sign language literacy and performance arts, Deaf identity and cross-cultural interaction.

Anita Small has obtained over eight million dollars in language and culture project grants and mentors non-profit organizations and individuals on effective grant writing. She spearheaded and served as content manager and co-creator of numerous award winning sign language productions (children’s books, videos, DVD’s and websites). She is recipient of a United Nations International World Summit/ UNESCO Award (2013) as co-creator of the Deafplanet educational television series and website www.deafplanet.com and of the International W3 Award (2012) for the first Animated American Sign Language (ASL) Dictionary for Children, www.aslphabet.com. Dr. Small established the Canadian Literary and Deaf Arts Awards of Excellence through the Canadian Cultural Society of the Deaf and the International Deaf Documentary Awards through Deaf History International.

Dr. Small has her Doctorate of Education in Sociolinguistics (1986) and Cultural Mediation and Dispute Resolution Training (1992). She has taught, consulted and mediated in the U.S., Canada, Japan, Italy and the Netherlands and has provided cross cultural interaction training and mediation with Deaf and hearing personnel for over 25 years. Dr. Small is recipient of the singular national award from the Canadian Deaf community (2006) given to a hearing individual.

www.anitasmall.com
Anna van Suchtelen (New York 1961) studied Literature (MA) in Groningen, the Netherlands and Visual Arts at University of California San Diego, USA. Over the years she professionally moved from literary editor to visual artist. Text and narrative play a crucial role in her visual work, which includes installations, audio works and film. Her projects, often context-specific and interactive, explore the senses, memory and time. Her work has been exhibited, performed and screened in the Netherlands, the United States, Canada, Italy, India and Japan.


http://www.annavansuchtelen-eng.kunstinzicht.nl/
Nancy K. Sweitzer, MD, PhD

"She is a physician scientist with expertise in advanced heart failure and transplant cardiology."

Nancy K. Sweitzer, MD, PhD, is Director of the University of Arizona Sarver Heart Center, Professor of medicine and Chief of the Division of Cardiology in the UA College of Medicine - Tucson. She is a physician scientist with expertise in advanced heart failure and transplant cardiology. Her scientific interests focus on clinical research in the area of heart failure, with expertise in clinical trials, and particular interest in early phase drug and device trials in heart failure, mechanical circulatory support and heart transplant.

Dr. Sweitzer’s research program has focused on the physiology of heart failure with preserved ejection fraction (HFpEF), with attention to decreased systolic reserve and vascular stiffening as important potential therapeutic targets. Recognized for her expertise in clinical trials, Dr. Sweitzer holds national leadership roles in several large multicenter trials of novel drug and device therapies in heart failure. She has led and collaborated on studies sponsored by the National Institutes of Health, foundation, industry and academic sponsors. She has served on numerous NIH committees and study sections, and regularly performs grant review for the American Heart Association.

Dr. Sweitzer joined the University of Arizona in 2014 after 12 years at the University of Wisconsin. At the Sarver Heart Center, she has established a robust clinical research program, focused on delivering efficient, effective clinical research services of the highest quality, with an emphasis on early phase studies, enrollment goals and regulatory compliance. The program administers numerous translational and clinical projects with a portfolio of Phase 2 and 3 trials reaching hundreds of patients each year. She is currently funded by the NIH and the AHA for projects involving early phase study of novel therapeutics, as well as proteomic and metabolomic study of heart failure. Much of her current research is focused on identification of novel druggable targets in the currently untreatable disease HFpEF.

Recently named editor-in-chief of the journal Circulation: Heart Failure, Dr. Sweitzer is active in many national societies, including the American Heart Association, The American College of Cardiology and the Heart Failure Society of America. She has served as an associate editor for the journal Circulation since 2016. She is on the Board of the Association of Professors of Cardiology, a group of US national leaders in cardiovascular medicine, and was inducted into the Association of University Cardiologists in January, 2017.
FACULTY BIOGRAPHIES

Uri Tabori, MD

"Dr Uri Tabori is a staff Oncologist and Clinician Senior Scientist at The Hospital for Sick Children in Toronto, Canada..."

Dr Uri Tabori is a staff Oncologist and Clinician Senior Scientist at The Hospital for Sick Children in Toronto, Canada.

He is also a Principle Investigator at The Arthur and Sonia Labatt Brain Tumour Research Centre at The Hospital for Sick Children in Toronto. Dr. Tabori an associate professor at the Departments of Medical Biophysics and Institute of Medical Science, at The University of Toronto, Faculty of Medicine.

Dr Uri Tabori’s research focuses on combining biological and translational research in Pediatric Oncology. Specifically, he is interested in studying mechanisms underlying brain tumor immortality and recurrence in the context of predisposition to cancer.

Dr. Tabori, is a Garron Family Chair in childhood cancer research and has been the recipient of numerous national/international awards for his outstanding contributions to biomedical research, The Canadian Cancer Society Bernard and Francine Dorval prize being amongst one of the most recent ones.
Dr. Timothy Triche is the founding Director for the Children’s Hospital Los Angeles Center for Personalized Medicine. He previously served as Chief of the Department of Pathology and Laboratory Medicine for over 20 years. He is also Professor of Pathology and Pediatrics at the Keck School of Medicine of the University of Southern California. At Children’s Hospital, his research is focused on high-risk childhood cancer, including molecular diagnostics and nanoparticle therapeutics, as part of an overall focus on ‘precision’ or ‘personalized’ treatment of childhood cancer. He is the author of over 250 peer reviewed publications and has received over $40 million in NIH or equivalent funding as PI, and has been a co-PI or co-investigator on over $100 million of other grants. He has also received over $5 million of private research funding.

He received his undergraduate degree in physics and biology from Cornell University in 1966, where he was a Cornell National Scholar, and MD and PhD degrees from Tulane University in 1971. He received his specialty training in pathology and surgical pathology at Barnes Hospital-Washington University School of Medicine, where he also did a post-doctoral fellowship in cancer-associated lectin biochemistry. He subsequently did a further fellowship at the NCI, which eventuated in a tenured faculty position at the NCI as Section Chief, Laboratory of Pathology, focused on pediatric cancer diagnosis, treatment, and research, a position he held for 14 years prior to coming to CHLA.

Dr. Triche has been actively engaged in biotechnology since 1980. Over that time, he has founded at least 8 companies, been the CEO of one, done an IPO, been on the board of numerous biotech and life science companies, and done due diligence for investment banking firms (e.g., Baird), consulting groups (e.g., PwC), and various family trusts. A particular focus has been next gen sequencing platforms, including Ion Torrent (now Thermo Fisher Scientific), Helicos, Pac Bio, Genclis, NabSys, Bina (now part of Roche), Genia (also now part of Roche), and NorthShore Bio.
Thorsten Vetter, MD

Thorsten Vetter, MD, Clinical Pharmacologist: 10 years in translational academic research (Internal Medicine, Endocrinology, Basic and Clinical Pharmacology); joined the European Medicines Agency in 2009 in the Office of Scientific Advice, providing Scientific Advice, Qualification Advice/Opinion on Novel Methodologies in Drug Development and HTA parallel Advice to interested parties; member of the core PRIME review team at EMA; regular involvement in different international initiatives to further regulatory science and advice, in particular with US FDA.

"10 years in translational academic research."
Lucy Wedderburn is a Professor in Paediatric Rheumatology at UCL (UCL GOS Institute of Child Health) and a Consultant at Great Ormond Street Hospital (GOSH).

She trained in Cambridge and then London in Immunology and Rheumatology and then spent time training in science in the University of Stanford, USA, before returning to University College London (UCL) and GOSH on a Wellcome Trust Fellowship. She has been at GOSH for more than 10 years as a consultant. Lucy's research group investigates the mechanisms of childhood autoimmunity and what controls immune responses. She is the PI of two large international translational research networks in the field of Paediatric Rheumatology (in childhood arthritis, JIA and myositis, JDM) and has led the development of databases now being used to enhance clinical care, research and specifically efforts in stratified medicine. Her current work includes introduction of a new biomarker for prognostic use in JIA and integration of proteomic/genetic/transcriptome data for biomarker discovery. She is Director of the Arthritis Research UK Centre for Adolescent Rheumatology at UCL ULCH and GOSH which aims to drive translational science in the field of Adolescent Rheumatology. She is the Deputy Director of the newly renewed NIHR Great Ormond Street Biomedical Research Centre. Lucy has been involved with the Eureka program and has led the UCL involvement in this programme since 2009.

“She trained in Cambridge and then London in Immunology and Rheumatology and then spent time training in science in the University of Stanford, USA…"
EUREKA Institute

OBSERVER FACULTY BIOGRAPHIES
Dr. Fornoni is tenured Professor of Medicine and Molecular and Cellular Pharmacology at the University of Miami Miller School of Medicine. She is the Chief of the Division of Nephrology and Hypertension and serves as and Director and Chair of the Peggy and Harold Katz Drug Discovery Center. She is also the Associate Director of the MD PhD program. In the year 2013, Dr. Fornoni gained experience in drug development as Global Head of Discovery in Cardiovascular and Metabolism at Hoffman-La Roche in Basel. She is currently the Vice-President and Chief Scientific Officer of L&F Health LLC, a small startup company focused on finding a cure for patients affected by chronic kidney diseases.

As a physician-scientist who has maintained a resolutely focused research program that has provided novel and seminal contributions to our understanding of the pathogenesis of kidney disease, her research has been supported by grants from National Institutes of Health, industry and private foundations. She has received prestigious awards, serves on the editorial board of Diabetes and other journals, has been invited to presents at national and international meetings in five different continents, and has served as visiting professor at more than 30 academic institutions. She serves as grant reviewer for NIH, DOD, ADA, AHA, UK-diabetes and the Italian Ministry of Health. Her contributions have been published in high impact journals: Journal of Clinical Investigation, NEJM, Nature Medicine, Science Translational Medicine, Journal of Biological Chemistry, and Diabetes among others. She successfully trained several graduate students and post-doctoral fellows, further supporting her accomplishments, dedication and perseverance, and more importantly her unstinted commitment as a physician-scientist.

Moving forward, her vision is one that brings industry, investors and not for profit organizations around the table with the intent to match science with innovation and patients’ motivation to find a cure for kidney diseases.
Mary M. Chen, MS, MBA

"Ms. Chen and her team have built a robust foundation for a clinical and research support office specialized in maternal child health..."

Mary Chen, MS, MBA, is the Assistant Dean of Maternal and Child Health Research at Stanford University School of Medicine, the Administrative Director of the Stanford Child Health Research Institute, and the Director of Spectrum Child Health within the Stanford Center for Clinical and Translational Research.

After completing her graduate degree in molecular microbiology and immunology at Johns Hopkins University, Ms. Chen began her career at Stanford as a research associate in cardiovascular medicine where she studied the genetic markers of atherosclerosis. Ms. Chen led a project comparing the transcription profiles of heart tissues from patients before and after receiving a left ventricular assist device. This work led to the discovery of a key modulator in heart failure called Apelin and subsequent generation of the Apelin knockout mouse model for further research in heart failure.

Ms. Chen joined Pediatrics in 2006 and began focusing her efforts in supporting maternal and child health research. Her interests in marrying the principles of business management and the rigors of scientific discovery led her to pursue a second graduate degree in business administration at Santa Clara University.

Ms. Chen and her team have built a robust foundation for a clinical and research support office specialized in maternal child health, including a dedicated research coordinator pool, study management services, seed funding for faculty and trainees, and a formal mentoring program for early-career investigators in pediatrics.

Ms. Chen continues to work with school leaders with the goal of building appropriate infrastructure to support maternal and child health research at Stanford. She leverages her understanding of the translational research process and her business skills, ensuring that clinical and translational research needs are adequately addressed.
**OBSERVER FACULTY BIOGRAPHIES**

**Karel G.M. Moons (Carl), PhD**

"Karel G.M. Moons is Professor of Clinical Epidemiology at the Julius Center for Health Sciences and Primary Care, UMC Utrecht."

Karel G.M. Moons is Professor of Clinical Epidemiology at the Julius Center for Health Sciences and Primary Care, UMC Utrecht, The Netherlands. He is Director of Research in the management team of the Julius Center and heading the research programme ‘Methodology’. Since 2005 he also has an Adjunct Professorship at Vanderbilt University, Nashville, USA. He also is affiliated to the Cochrane Collaboration and Cochrane Netherlands. He is editor in chief of BMC Diagnostic & Prognostic Research.

Karel Moons is principal investigator in numerous international (epidemiologic and clinical) studies funded by various organisations (EU, NHS, NIH). His experience covers the full range of conduct, data analysis and reporting of such studies, varying from diagnostic test evaluation, etiologic and prognostic (bio)marker studies to therapeutic trials and meta-epidemiological studies. His main focus concerns the methodology of diagnostic and prognostic research, both primary and meta-analytical research. His major expertise is testing and introducing innovations for design and analysis for development, validation and implementation of diagnostic and prognostic biomarkers and prediction models. Clinical topics include cancer, deep vein thrombosis, heart failure and peri-operative risk assessment. He teaches graduate and postgraduate students in all aspects of epidemiologic and clinical research design, analysis and reporting, throughout the world. He has published over 425 scientific papers and book chapters and obtained numerous (methodological and applied) research grants, including large prestigious personal grants.
Kee Chong Ng, MD

"Kee-Chong is currently Chairman of Division of Medicine, KK Women’s & Children’s Hospital (KKH) in Singapore..."

Adjunct Associate Professor, Duke-NUS MS & YLL SoM; Chair Division of Medicine, Campus Director Medical Innovation & Care Transformation (MICT) & Senior Consultant, Emergency Medicine, KK Women’s and Children’s Hospital (KKH); Chair, Academic Clinical Program (Paediatrics) Singhealth-DukeNUS; Paediatrics Clerkship Director, DukeNUS; Member ILCOR Pediatrics Taskforce; Member of Singapore National Trauma Committee; Member of Singapore National Resuscitation Council (NRC) and Chairman of the Paediatric Life Support Subcommittee, NRC; Council member of the College of Paediatrics & Child Health, Academy of Medicine, Singapore.

Kee-Chong Ng is currently Chairman of Division of Medicine, KK Women’s & Children’s Hospital (KKH) in Singapore and Chair of the Paediatrics Academic Clinical Program in Singhealth-DukeNUS. He is also Campus Director of KKH’s Medical Innovation & Care Transformation (MICT).

He is a paediatric emergency paediatrician by training and was Head of Children’s Emergency at KKH from March 2005 to 2016. He did a clinical fellowship in Paediatric Emergency Medicine at the Hospital for Sick Children in Toronto, Ontario, Canada.

Kee-Chong is an Adjunct Associate Professor with the Duke-NUS MS and YLL SoM and was previously a member of the Specialist Training Committee (Emergency Medicine). He is currently a member of the Paediatric Residency Advisory Committee (RAC) as well as examiner for the Royal College of Paediatrics & Child Health in UK. He sits on the Duke-NUS Admissions Committee and is also a council member in the College of Paediatrics & Child Health, Academy of Medicine of Singapore.

Since 2011, he has been a member of the International Liaison Committee on Resuscitation (ILCOR) Pediatrics Taskforce. He was co-chair of the 2009-2011 MOH Toxicology CPG Workgroup and was Paediatrics section editor for the Asian Emergency Medicine Textbook. He is a member of the MOH National Trauma Committee and a member of the National Resuscitation Council (NRC) and Chairman of the Paediatric Life Support Subcommittee of the NRC. He was appointed to the protem committee of the Singapore Resuscitation & First Aid Council (SRFAC) in 2016. He has led various regional outreach teams to teach paediatric resuscitation using the train-the-trainer frameworks in Cambodia, Laos, Myanmar and in China. His interests include paediatric disaster response & planning; paediatric resuscitation; paediatric toxicology and regional clinical outreach and training.
OBSE RVER FACUL TY BIOGRAPHIES

Rosalind L Smyth, CBE, MA MBBs, MD, FRCPCH, FMedSci

"Her research interests include viral/host interactions in the airways, drug safety and efficacy in children."

Rosalind Smyth is Director of the UCL Institute of Child Health and Honorary Consultant Respiratory Paediatrician and non-executive director of Great Ormond Street Hospital NHS Foundation Trust. She graduated in medicine from Clare College, Cambridge and Westminster Medical School and trained in paediatrics in London, Cambridge and Liverpool. Until September 2012, she was Professor of Paediatric Medicine in at the University of Liverpool and was Director of the NIHR Medicines for Children Research Network, which supported all clinical research with children in England, from 2005-2012. She was a member of the UK MHRA's Commission on Human Medicines Committee 2009-13 and chaired its Paediatric Medicines Expert Advisory Committee (2002-13) Her research interests include viral/host interactions in the airways, drug safety and efficacy in children.

Rosalind is a fellow and recent council member of the Academy of Medical Sciences (AMS) and through the Academy has a number of national roles in academic training and careers. She is a member of AMS Mentorship Advisory Committee since 2015, a judge and organiser at AMS Spring Meeting since 2014 and has represented the Academy on NIHR Dean's Advisory Committee since 2010. Most recently, she has been appointed Chair of the MRC Clinical Training and Careers Committee, from April 2017.

She was awarded Commander of the Order of the British Empire in the Queen's New Year's Honours List in 2015 for services to the regulation of medicines for children.
**PARTICIPANTS BIOGRAPHIES**

**Roberta Brambilla, PhD**

Roberta Brambilla is an Assistant Professor of Neurological Surgery at the Miami Project To Cure Paralysis, a center of excellence in neuroscience research of the University of Miami Miller School of Medicine. After obtaining her Ph.D. from the University of Milan, she moved to the University of Miami where she trained as a post-doc before starting her independent research lab.

Dr. Brambilla’s main interest is to understand the role of neuroinflammation in the pathophysiology of neurodegenerative disorders like multiple sclerosis, spinal cord injury and stroke, with a specific focus on the contribution of glial cells. In recent years she has devoted her efforts to investigating the function of tumor necrosis factor (TNF), both membrane-bound and soluble forms, in neuroimmune disease. Within this context, she is exploring the protective signaling initiated by the interaction of membrane-bound TNF with TNFR2, taking advantage of cell-specific conditional knockout mice with ablation of TNFR2 from various CNS and immune cell populations, including astrocytes, microglia/macrophages, oligodendrocyte precursors and myelinating oligodendrocytes. Another important research topic being developed in her lab is understanding how mitochondrial dysfunction in oligodendrocytes might play a role in multiple sclerosis etiopathogenesis. Using novel genetic tools, she is investigating whether this mechanism causes primary oligodendrocyte cell death and demyelination, leading to disease initiation.

**Joyce Browne, MD, PhD**

Joyce Browne is a medical doctors and epidemiologist. The driving force behind her research interest is the persistent global inequity in reproductive, maternal and perinatal health, and urgent need to improve this.

She graduated cum laude from University College Utrecht with a major in pre-medical sciences and a minor in public health and development studies. Subsequently, she completed an MSc in Social Epidemiology at University College London, United Kingdom (2010), and postgraduate medical studies (Selective Utrecht Medical Master, SUMMA) at Utrecht University (2013). In 2016 she defended her PhD in Clinical Epidemiology at Utrecht University with the title ‘Improving maternal health in urban low resource settings’.

She is currently an Assistant Professor in Global Health at the Julius Center for Health Sciences and Primary Care at the University Medical Center Utrecht, and focuses on global health and maternal health research.

Joyce is a board member of the Netherlands Society of Tropical Medicine & International Health (NVTG) and the NVTG’s working group for young researchers in global health, Uniting Streams. She was selected as a ‘Young Face of Science’, in the Dutch Royal Academy of Sciences’ (KNAW) initiative that provides a platform for young researchers to share their research with the general audience.
PARTICIPANTS BIOGRAPHIES

Giulio Cavalli, MD

I received a Medical Degree magna cum laude from Vita-Salute San Raffaele University (Milan, Italy) in 2011, completed residency and fellowship in Clinical Immunology at the same Institution in 2016, and stayed on as lecturer and attending physician in the Unit of Immunology, Rheumatology, Allergy and Rare Diseases. I soon realized that the application of existing knowledge in clinical practice did not fulfill my need to think creatively and leave a mark of my own, and developed a strong focus on research. I first became absorbed in the study of cancer related-inflammation in Erdheim-Chester Disease, and was introduced to a vibrant network of scientists that was ideally suited for the development and pursuit of my research interests, both at my home Institution and abroad. In particular, I recently completed a 2-year visiting Postdoc at the University of Colorado in Denver (Aurora, CO) in the laboratory of Prof. Charles Dinarello, with whom I investigated the genetic risk of developing immune-mediated conditions, and explored targeted therapies for the innovative treatment of various inflammatory conditions. In addition to my current clinical and research activity at my home Institution, I am involved in research projects at the Radboud University Medical Center in Nijmegen (The Netherlands), in collaboration with Prof. Leo Joosten.

Elizabeth Gibbs, PhD

Elizabeth Gibbs is a postdoctoral fellow in the Department of Integrative Biology and Physiology at UCLA. Her long-term research focus is centered on understanding cellular and molecular mechanisms underlying childhood muscle disorders, and on identifying new therapeutic approaches for these conditions. She received her master’s degree and Ph.D. in Neuroscience at the University of Michigan (2006-2012), where she generated novel zebrafish models of congenital muscle disorders, and identified previously unknown disease mechanisms in centronuclear myopathy, a severe pediatric muscle disorder. After completing her Ph.D, Dr. Gibbs spent a year at the Center for Brain Development at UCSD (2012-2013), where she characterized gene variants in a cohort of individuals with genetically undiagnosed pediatric neurological disorders. As a current postdoctoral fellow at the UCLA Center for Duchenne Muscular Dystrophy (2013-present), Dr. Gibbs’s research focuses on understanding the pathways involved in establishing and maintaining muscle membrane stability, and on identifying potential therapeutic targets in Duchenne muscular dystrophy and related inherited muscle disorders.
Natalia Gomez-Ospina, MD, PhD

I was born and raised in Medellin, Colombia where I began my undergraduate studies in petroleum engineering at the Universidad Nacional de Colombia before moving to the United States. I matriculated at the University of Colorado Boulder, where I graduated summa cum laude while double majoring in molecular, cellular, and developmental biology, and biochemistry. My research career began as an undergraduate student performing ultra-structural studies using advanced electron microscopy. I developed three-dimensional reconstruction of nuclear envelopes to quantify and phenotype nuclear pore mutants, and contributed to the first reconstruction of the Golgi apparatus in Pichia Pastoris using high-voltage electron microscopy and tomography.

To combine basic science and medicine, I pursued training as a physician scientist through the medical scientist training program at Stanford University School of Medicine. My graduate training was in molecular neurobiology, where my PhD work focused on understanding novel functions of voltage-gated calcium channels. I chose to then pursue clinical training in medical genetics specifically for the opportunity to combine medicine and basic science. The amazing specialty has allowed to learn and contribute to our understanding of multiple genetic disorders including infantile cholestatis, newfound intellectual disability syndromes, Costello syndrome, Pierre-Robin sequence, and Hawkinsinuria.

My training as a geneticist exposed the lack of effective interventions for many genetic diseases, and led to my decision to make intervention the focus of my future research and clinical efforts. I decided to focus on lysosomal storage disorders (LSDs) because they represent a large unmet clinical need, and the disease pathophysiology is amenable to correction. My clinical responsibilities, which include managing the enzyme replacement service for the treatment of LSDs, have allowed me to learn in-depth about this group of diseases and acquire first-hand experience with their present management, their outcomes, and the limitations of our interventions. In the lab, I have begun the development of genome editing tools to target the common LSDs, Mucopolysaccharidosis type I and Gaucher type I by engineering human hematopoietic stem cells.

Marne Hagemeijer, PhD

Marne Hagemeijer is a postdoctoral researcher in the department of Pediatric Pulmonology at the University Medical Center Utrecht (UMCU) in the Netherlands. He obtained his Ph.D. degree in 2011 at the Virology Division of the Faculty of Veterinary Medicine at Utrecht University in the laboratory of prof. dr. Peter Rottier under the supervision of dr. Xander de Haan. His research focused on the assembly, dynamics and functioning of the coronavirus replication structures in infected cells with the goal to identify novel therapeutic opportunities. Following the completion of his Ph.D. he moved to the United States to work among others at the Cell Biology and Physiology Center at the National Heart, Lung and Blood Institute (NHLBI) at the National Institutes of Health (NIH) in the laboratory of dr. Nihal Altan-Bonnet. As a postdoctoral research fellow he continued and extended his scientific research on positive-strand (+)RNA viruses, together with extensive training in various state-of-the art microscopy techniques, including PALM/dSTORM and structured illumination microscopy. During this three-year period abroad, he studied the nanoscale molecular organization and structure of viral and host components of +RNA virus replication organelles using a combination of super resolution microscopy techniques and live cell imaging approaches. Currently, dr. Hagemeijer is part of the group of dr. Jeffrey Beekman (UMCU, the Netherlands) in the laboratory of prof. dr. Kors van der Ent where he conducts research on cystic fibrosis (CF), specifically focusing on the development and identification of novel CFTR-restoring therapeutic approaches and its clinical relevance for CF patients by combining organoid technology with high-content screening (HCS) approaches.
PARTICIPANTS BIOGRAPHIES

Linda Hiraki, BSc, MD, FRCPC, SM, ScD

Dr. Linda Hiraki is a Clinician-Scientist in the Division of Rheumatology, a Scientist-Track investigator in the Child Health Evaluative Sciences program at the Hospital for Sick Children (SickKids) and Assistant Professor in the Department of Paediatrics, and the Department of Epidemiology, Dalla Lana School of Public Health, University of Toronto. Dr. Hiraki completed her medical degree at Queen’s University, Kingston, Canada and her clinical training in paediatrics and rheumatology at SickKids. She is certified by the Royal College of Physicians and Surgeons of Canada in the specialties of paediatrics and paediatric rheumatology. Dr. Hiraki went on to receive the prestigious Harvard Frank Knox Memorial Scholarship in support of her research training at the Harvard T.H. Chan School of Public Health where she completed a Masters and Doctor of Science in Epidemiology. She also completed postdoctoral training in the laboratory of Andrew Paterson, a Senior Scientist studying Genetics & Genome Biology at SickKids. Dr. Hiraki is coordinating a large, international cohort of systemic lupus erythematosus patients followed prospectively over years of disease to understand the genetics of lupus, its many manifestations, the disease course and related outcomes.

Saumya Shekhar Jamuar, MBBS, MRCPCH

Dr Saumya Jamuar is a Consultant in the Genetics Service at KKH and serves as the Clinical Lead of the Precision Medicine Initiative and Singapore Childhood Undiagnosed Disease Programme. He completed his Genetics Fellowship at the Harvard Medical School Genetics Training Program and worked as a post-doctoral fellow in Christopher A Walsh lab in Harvard Medical School from January 2012- December 2013. He is actively involved in research and has presented at both local and international meetings. His research areas include genetic disorders, dysmorphology, skeletal dysplasia, and neurodevelopmental genetics. He was awarded the Young Investigator Award at the American Epilepsy Society meeting for his work on targeted resequencing on patients with epileptic encephalopathy. He is also the recipient of the 2015 Singhealth Outstanding Young Researcher Award.
PARTICIPANTS BIOGRAPHIES

Jason H. Karnes, PharmD, PhD, BCPS

I received my Bachelor of Arts degree in Ancient Greek from the College of William and Mary. In 2004, I moved to Gainesville, FL to pursue a Doctor of Pharmacy at the University of Florida, which I completed in 2008. I remained at the University of Florida to pursue a Doctor of Philosophy in Clinical Pharmaceutical Sciences. My graduate work focused on the pharmacogenomics of adverse metabolic effects of antihypertensive drugs under the mentorship of Drs. Julie Johnson and Rhonda Cooper-DeHoff. In August 2012, I began a research fellowship in the department of Clinical Pharmacology at Vanderbilt University under the mentorship of Dr. Dan Roden. At Vanderbilt, my research studies focused on cardiovascular pharmacogenetics and I served as the Jason D. Morrow Chief Fellow for the Division of Clinical Pharmacology. In September 2015, I joined the faculty at the University of Arizona College of Pharmacy in the Department of Pharmacy Practice and Science. Since graduating from pharmacy school, I have continuously practiced pharmacy in hospital and retail settings and maintained board certification in pharmacotherapy. My long term research objective is to determine biomarkers for serious adverse reactions, especially heparin-induced thrombocytopenia, and translate this knowledge into personalized drug treatment in patients. I am an author on eighteen peer-reviewed manuscripts and twenty three abstracts presented at national and international meetings. I am active in multiple professional societies including the American Heart Association, American Society for Clinical Pharmacology and Therapeutics, and the American College of Clinical Pharmacy. I have been awarded a Scientist Development Grant from the American Heart Association and a Futures Grant from the American College of Clinical Pharmacy Research Institute.

Meena Kadapakkam, MD

I am currently a second year Pediatric Hematology/Oncology Fellow at Stanford University. I completed my undergraduate studies in Biomedical Engineering at the University of Texas at Austin, attended medical school at Baylor College of Medicine, and completed my pediatric residency training at the University of Texas Southwestern. My research focus is developing immunotherapy for neuroblastoma. I hope to pursue a career in translational medicine upon completion of my fellowship.
PARTICIPANTS BIOGRAPHIES

Belinda van’t Land, PhD

Belinda van’t Land is a senior scientist within the Immunology Department of Nutricia Research. She has developed a strong basis in developmental immunology and knowledge on the role of infections and diet in early life. She started her career in the late 90’s at the University of Uppsala in Sweden within the group of Prof. K. Lövgren-Bengtsson, initiating a first interest in immunology and resulting in a publication entitled: “Iscoms containing purified Quillaja saponins upregulate both Th1-like and Th2-like immune responses”. The understanding of viral protein processing and MHC-I presentation was further studied in collaboration at the Virology Department of the Erasmus University in Rotterdam within the group of Prof. Ab Osterhaus. There the immune pathology of RSV infection in early life attracted a long lasting interest and drive to understand the complex development of a functional host microbiological balance in early life and alterations during (chronic) disease. The role and development of the mucosal immune system was studied in collaboration with the Nijmegen University in the Lab of Prof T de Witte in which the role of nutrition became a permanent factor and key aspect of interest within the establishment of mucosal immunity.

Finalizing her PhD, Belinda learned that fundamental research is essential to understand new innovations and translation is necessary to bring these to the individuals who might benefit most, thereafter accepting a scientist position within Nutricia Research. Becoming a parent of three, and knowing that infants are born, not immune compromised, but with specific needs supporting their immune development, she continued her research within the field of early life immunity, the mucosal immune response and effect of nutritional interventions. In collaboration with the UMCU/Wilhelmina’s Children’s Hospital, they developed a great research team consisting of 3 PhD students, a post-doc and Sr assistant scientist, building together on the understanding of early life immune development. The research program is focused on studying the complex interplay between nutrition and immunological development in early life. Belinda van’t Land has managed and initiated several multidisciplinary projects and collaborations that have contributed to the scientific understanding of nutritional innovations as well as the development of new treatment approaches. Her current research is a wonderful example of use-inspired research with a focus on applied research, but also including strategic and fundamental work, from molecule to concept and from concept to patient benefit, especially in a (chronic) disease setting.

Julie Ledford, PhD

Dr. Ledford is an assistant professor of medicine and immunobiology at the University of Arizona and is an active member of the Asthma and Airway Disease Research Center, the BIOS Institute, the Southwest Environmental Health Sciences Center and has faculty appointments in the Graduate Interdisciplinary Program in the Physiological Sciences and in the Allergy and Immunology Fellowship Training program. She received her PhD training in Genetics and Molecular Biology at the University of North Carolina at Chapel Hill and completed her postdoctoral training in surfactant immunobiology at Duke University. Dr. Ledford’s research interests are centered around pulmonary proteins that are secreted and reside within the air-lung interface and mediate immunity to inhaled pathogens and allergens. Of particular interest are two proteins, which are among the most highly expressed pulmonary proteins in humans: Surfactant Protein-A (SP-A) and Club Cell Secreted Protein (CCSP). Working closely with clinical translational collaborators, her research team has discovered that some asthmatics express a genetic variant in SP-A that renders them more likely to have lower lung function, worse asthma control and higher levels of peripheral eosinophils. Based on these findings, her current research is focused on drug development with an SP-A 10 AA peptide that can rescue the activity of the dysfunctional SP-A allele. Additionally, Dr. Ledford’s group has discovered that obese asthmatics have less SP-A in their lungs, which may contribute to a decreased ability to clear eosinophils from the lung tissue. Working with a team of clinicians and basic scientists, they are exploring mechanisms by which obese asthmatics would have less SP-A as compared to lean asthmatics, which may be a consequence of a heightened cytokine milieu coupled with increased chest wall pressure.
**PARTICIPANTS BIOGRAPHIES**

**Baskaran Mani, MBBS, DO (Ophthalmology), DNB (Eye), PhD**

Asst Prof (Dr) Baskaran Mani, is a Clinician Scientist in Singapore Eye Research Institute and Singapore National eye Centre, with special interest in glaucoma and eye diseases. He has a PhD from Yong Loo Lin School of Medicine, NUS, Singapore. Formerly, a glaucoma specialist from India, he participated in several clinical and epidemiological studies in glaucoma from both India and Singapore. He is also concurrently the Assistant Professor at the Office of Clinical, Academic and Faculty affairs, EYE-ACP, Duke-NUS graduate Medical School. He has more than 140 peer-reviewed publications, 60 invited talks in international conferences, 8 book chapters and 7 co-patents for inventions in the field of glaucoma imaging and diagnostics. His research interests include imaging in glaucoma, clinical trials and biomedical devices. His current project is in translational pre-clinical studies in primates with ocular hypertension and trabecular meshwork imaging with biomechanical end points. His current major research interests include clinical trials in glaucoma, innovations in ocular biomedical devices, ocular imaging and software applications for automated evaluation and home care including wireless applications, Trabecular meshwork imaging, biomechanics and stem cell therapy and glaucoma progression modeling.

---

**Heidi M. Mansour, PhD**

Dr. Heidi M. Mansour is an Assistant Professor in the College of Pharmacy (Dept of Pharmaceutical Sciences and Pharmacy Practice & Science), College of Medicine (Division of Translational & Regenerative Medicine), and the BIOS Research Institute at The University of Arizona (UA) in Tucson, Arizona (USA). Dr. Mansour is also faculty member in the UA Institute of the Environment and the UA NCI Comprehensive Cancer Center. She is an elected Fellow of the Royal Society of Medicine, Co-Chair of the Drug Delivery: New Devices & Emerging Therapies Group in the International Society of Aerosols in Medicine (ISAM), and has been an expert member of NIH NICHD U.S. Pediatric Formulations Initiative New Drug Delivery Systems Aerosols Working Group for several years. She received the NIH Service Award with Continuous Submission Privileges for extensive NIH study section reviewer service. She regularly serves as an expert reviewer for scientific journals and grant funding agencies including NIH study sections, NSF study panels, AAAS, Catalent Drug Delivery Institute and international funding agencies such as the German-Israeli Foundation, German International Exchange Service (DAAD), Cochrane Airways Group of the National Health Service (London, England), Engineering and Physical Sciences Research Council (London, England), PRESTIGE Fellowship Programme of the European Commission (Paris, France), the Biomedical Innovation Program of the French National Research Agency (Paris, France), the Medical Research Council (London, England), and European Union Transnational Program in Materials Research & Innovation (Portugal). In addition to presenting two webinars on therapeutic inhalation aerosols for precision pulmonary medicine, she has published 80 peer-reviewed scientific journal papers, 9 book chapters, over 100 scientific conference abstracts, and two scientific research educational webinars. She is co-editor of a nanomedicine book published in 2013 and co-editor of an inhalation aerosol translational medicine third edition book (due in 2017), both published by CRC Press/Taylor & Francis. Dr. Mansour is an Editorial Board member for 6 journals in medicine, engineering, and pharmaceutical sciences. Her research program has enjoyed funding from federal sources and the pharmaceutical industry. In addition to lecturing in the Graduate Ph.D. and Pharm.D. programs, Dr. Mansour leads her research lab where she trains postdoctoral scholars, visiting scholars, biomedical engineering students, PharmD/PhD graduate students, and physician-scientist (MD/PhD) fellows. Her research program has produced a number of Assistant Professors employed at research universities in the United States and in the Republic of S. Korea and Senior Research Scientists employed at major pharmaceutical companies in the United States. Dr. Mansour is an active, long-time member of numerous scientific organizations and elected member to honor societies, including the Sigma Xi Scientific Research Honor Society, Rho Chi Pharmaceutical Honor Society, and Golden Key International Honor Society. She serves on the editorial advisory boards for several journals. She has a BS in pharmacy with honors and distinction, a PhD minor in advanced physical and interfacial chemistry (Department of Chemistry), and a PhD major in drug delivery/pharmaceutics (School of Pharmacy) from the University of Wisconsin-Madison. She completed postdoctoral fellowships at the U.W.-Madison and at the University of North Carolina-Chapel Hill receiving the UNC-Chapel Hill Postdoctoral Award for Research Excellence from the Office of the Vice-Chancellor, the AAPS Postdoctoral Fellow Award in Research Excellence, and the PhRMA Foundation Postdoctoral Fellowship award. As an Instructor, she served on the Graduate Faculty at UNC-Chapel Hill.
PARTICIPANTS BIOGRAPHIES

Melissa Mavers, MD, PhD

Melissa Mavers is currently in her third year of fellowship training in Pediatric Hematology and Oncology, with a research focus and clinical interest in stem cell transplantation. She completed her MD degree and PhD in Molecular Microbiology and Immunology in the laboratory of Dr. Harris Perlman where she investigated the role of the cyclin dependent kinase inhibitor p21 in suppression of inflammatory cytokine production and treating inflammatory diseases. She then completed her Pediatrics residency training at the University of California Los Angeles, and subsequently entered the Pediatric Hematology and Oncology fellowship program at Stanford University. She is conducting her current research in the laboratory of Dr. Robert Negrin where she is investigating expansion and enhancement of function of immunoregulatory cells in stem cell transplantation for suppression of acute graft-versus-host disease. Next year she will continue her research as an Instructor in Pediatric Stem Cell Transplantation and Regenerative Medicine at Stanford. She plans a career as an academic physician-scientist in this field using cutting edge technology to investigate immune modification for the prevention of GVHD and translating laboratory findings into clinical protocols that make stem cell transplantation a safer way to cure cancer and other diseases.

Eoin McKinney, BA, MBChB, MRCP, PhD

Eoin studied clinical medicine in Keble College, Oxford University and then Edinburgh University before obtaining his PhD from Pembroke College, Cambridge University in 2011. After his PhD he has continued to work in the Cambridge Institute for Medical Research as a Wellcome-Beit Research Fellow in with Professors Ken Smith and David Jayne in a programme of translational research in autoimmune disease in addition to working as a nephrologist in Addenbrooke’s Hospital, Cambridge. His research uses a ‘systems immunology’ analysis of immune cell transcriptomes isolated from patients with a broad range of autoimmune, inflammatory and infectious diseases. A major focus of this work to date has been the identification of pathways driving and marking severe, relapsing autoimmune disease with a view to developing predictive biomarkers but also informing our understanding of the underlying biology and identifying novel therapeutic targets. With a recent focus on T cell differentiation states, including T cell exhaustion, he has explored parallel ways in which the immune response deals with persistent infection and persisting self-antigen using a combination of transcriptomic data from untreated autoimmune patients and cellular models of primary human T-cell differentiation.
Basma Mohamed Medhat, MD

Basma Medhat is a lecturer of Rheumatology in Cairo University. She graduated from the Faculty of Medicine in 2006 with excellent with honors. Basma started her carrier as a rheumatologist in 2008, when she became a resident of rheumatology and has been promoted several times until she became a lecturer in 2015. She obtained her master’s degree in 2012 and her MD degree in 2014. She is currently working on several research projects, with her main interest being in Systemic lupus erythematosus.

Madhvi Menon, PhD

I am a Postdoctoral Research Associate at University College London. My research focuses on unravelling the mechanisms by which interferon alpha (IFNα) modulates B cell responses in health and autoimmunity.

I obtained my PhD in Immunology in 2015 from University College London. During my PhD, I discovered a novel crosstalk between plasmacytoid dendritic cells (pDCs) and regulatory B cells (Bregs) in healthy individuals that is aberrant in patients with systemic lupus erythematosus (SLE). I found that the level of exposure to IFNα is critical in determining the fate of B cells; B cells can acquire regulatory or pathogenic functions based on the micro-environmental IFNα levels. I am currently working on translating these findings to the clinic, by testing a novel combination therapy of anti-IFNα and B cell depletion therapy for treating SLE patients that display an elevated IFNα-induced gene signature. I was awarded the Bright Sparks in Immunology prize at the BSI/ NVVI Congress 2016, and have been selected to be a member of the British Society of Immunology Congress Committee in 2017.
PARTICIPANTS BIOGRAPHIES

Ghassan (Gus) Mouneimne, PhD

Research in my laboratory is focused on understanding how aberrant structural organization of the cytoskeleton influences cellular behavior, such as cancer cell invasion and metastasis. We are demonstrating that distinct actin cytoskeletal architectures impact the response of cancer cells to intrinsic factors, such as genetic alterations, or extrinsic factors, such as changes in the tumor microenvironment. The regulation of cellular behavior by structural remodeling of the cytoskeleton exemplifies the paradigm of “structure regulates function” at the cellular level. This paradigm deviates from the simplistic view that cancer cells acquire invasive phenotypes primarily due to the deregulation of signal transduction pathways that have been associated with malignant transformation.

Currently, we are investigating estrogen receptor (ER) regulation of invasion of ER positive (ER+) breast cancer by focusing on hormonal regulation of the actin cytoskeletal architecture. Our studies could ultimately present a novel treatment strategy in clinical practice, under which the common use of anti-estrogenic drugs might be reconsidered, especially for patients who developed ER+ tumors while under hormone deprivation (under hormone therapy or after menopause). More importantly, if successful, our studies will provide more rationale as to why it is crucial to re-think the current treatment strategies for ER+ cancer using endocrine therapy, and to move toward therapies combining anti-estrogenic drugs or estrogen agonists with potential actin cytoskeletal modulating drugs that we need to develop and validate in the laboratory.

Adeline Ng Su Lyn, MD

Consultant Neurologist, National Neuroscience Institute, Tan Tock Seng Hospital

Dr Adeline Ng is a consultant neurologist at the National Neuroscience Institute (TTSH Campus). She has a keen interest in cognitive and behavioural neurology, and recently completed a one-year fellowship at the Memory and Aging Centre, University of California, San Francisco, focusing on Young-Onset Dementias (YODs). Her main interests in clinical research are on frontotemporal dementia (FTD) and early-onset Alzheimer’s disease (EOAD), particularly in relation to their neuropsychological and clinical characterization, as well as the biological and genetic underpinnings of Asian patients with FTD and EOAD

Personal dilemmas
I am a clinician currently starting out my research career having recently obtained my first national level competitive grant. My research work (field of young-onset dementia genetics and biomarkers) occupies 20-30% of my time, with clinical and teaching duties making up the rest. Juggling clinical duties, research and 2 children has not been a problem for me as I enjoy the research that I do. However, over the last 2 years I have found that the biggest challenge for me has been navigating interpersonal dynamics and politics that are inevitable in the research field. Senior colleagues in the same field may sometimes feel threatened by “new blood” and either consciously or subconsciously hinder your progress, or end up competing with you in your areas of interest that they were previously uninterested in. This is especially challenging to navigate as we are still heavily reliant and dependant on each other’s patient data and samples. Furthermore, collaborating across institutions can be tricky for a young researcher not familiar with protocols, or the individual personalities and histories of established PIs who (as we are often told) may have their own agendas. Lastly, as a clinician-researcher, patients are my primary focus, and while it always remains a struggle to recruit patients for research studies in the Asian cultural context, especially if invasive procedures like a lumbar puncture are involved, I am heartened to see more and more patients start believing in what we do. I often worry that at the end of the day all the research we do amounts to nought; but I’m guessing all researchers deal with self-doubt on a regular basis!
PARTICIPANTS BIOGRAPHIES

Maryam Rakhshandehroo, PhD

I am Maryam born in Tehran Iran. I enjoyed my life in Iran and accomplished my Bachelor degree in field of Nutrition and health from Beheshti University. I always had the ambition to continue my studies abroad. Shortly after my Bachelor, I moved to Wageningen University in Netherlands. Wageningen is a very attractive student village. I started a new student life and learned to be independent and explored new people and a new world. My MSc course period has been one of the shiniest phases of my life. I made my best friends and also got the chance to travel to new countries. While finishing my MSc course I got interested in field of nutrition and genetics which made me to do a PhD and Postdoc in the field. After a few years of research, I got fascinated to learn more about business aspects of my career and discover the unknown Industrial world. It is now three years that I have moved to Utrecht and work for Nutricia Research. I desire new experiences, new challenges, and new discoveries.

Annet van Royen-Kerkhof, MD, PhD

Department of Paediatric Immunology and Rheumatology, Wilhelmina Children's Hospital, University Medical Centre Utrecht, the Netherlands.

As a paediatric immunologist and rheumatologist my main focus is on treatment of children with systemic auto-immune disease, such as Juvenile Dermatomyositis (JDM), Systemic Lupus Erythematosus (SLE), vasculitis, scleroderma. The Wilhelmina Children's Hospital is a tertiary referral centre for systemic auto-immune disease in children, with options for intensive treatment such as stem cell transplantation. Our clinical work is closely interrelated with fundamental research from the Lab of Translational Immunology (dr. van Wijk). This led to better insight on the effects of stem cell transplantation in pediatric rheumatic disease. (Blood 2016). For JDM we successfully identified biomarkers (e.g. galactine-9) for monitoring disease activity. (PLoSOne 2014, Arthritis&Rheumatol 2014). To optimize assessment of physical activity in children with musculoskeletal inflammation, close collaboration with the child development & exercise centre (dr. van Brussel) rendered insight in training capacity in JDM patients (Rheumatology 2016). Together with Technical University of Eindhoven (dr. Lopata) and the Department of Radiology of the University Hospital Utrecht, non-invasive techniques for imaging of inflamed muscle and skin are developed. (Scan J Rheumatol 2014, Muscle and Nerve 2015)

Results of abovementioned collaborations are discusses in a national multidisciplinary platform (“MyoInflammation”) of which I am currently holding chair. We actively collaborate with large centres in the world (London, Liverpool, Toronto, Bethesda USA (prof Rider), working on improvement of disease scoring systems, identification of risk profiles for severe disease course (Arthritis&Rheum 2016), and recommendations for diagnosis and treatment of JDM. (Annals Rheum Dis 2016). In close contact with patient organisations we focus on patient driven research, resulting in current project regarding symptoms of Fatigue and Fatigability.

During my fellowship in pediatric immunology I started teaching in small working parties in the conventional preclinical medical training programme in the UMcu, which I found very interesting. From February 2004, I took part in a medical research master SUMMA (Selective Utrecht Medical MAster) as a teacher and tutor. This programme was developed to train students with a Bachelors degree in Life Science or Biomedical studies to become clinician-scientist. In June 2016 I started as program director of this program. I participated in the International Medical Educators eXchange program (IMEX). My specific goal for participation in the Eureka Institute for Translational Medicine is to gain knowledge and inspiration to further shape and develop the SUMMA program.
Elizabeth (Beth) Sage, MBBS, PhD, MRCP

Dr Beth Sage is an NIHR Academic Clinical Lecturer and Specialist Registrar in Respiratory Medicine in North West London. She completed a degree in Physiological Sciences at Oxford University before going on to study Medicine and graduated from St George’s Hospital Medical School in 2003. In 2009 she was awarded and MRC Clinical Training Fellowship to undertake a PhD with Professor Sam Janes to develop a genetically modified cellular therapy for the treatment of malignant mesothelioma. On completion of her PhD she worked with Professor Janes and his team to secure funding from the Medical Research Council Developmental Pathway Funding Scheme to run a first in man clinical trial using genetically modified cell therapy for the treatment of metastatic lung cancer. She is a co-investigator on the TACTICAL trial (TArgeted stem Cells expressing TRAIL as a therapy for lung CAncer) which is due to start recruiting patients in 2017. Her other research interest is to understand more about how stem cells behave when delivered to patients with cancer and their interaction with the immune system to improve the efficacy of future treatments. I am an NIHR Academic Clinical Lecturer and Respiratory Registrar in North West London. I undertook my PhD in cell and gene therapy with Professor Janes at UCL and during this developed and genetically modified cell therapy to treat thoracic malignancies. Having completed my PhD, I successfully obtained my clinical lecturer post and have continued to work with Professor Janes on delivering the therapy developed in my PhD to patients in a first in man clinical trial. I am a Co-Investigator on the TACTICAL (TArgeted stem Cells expressing TRAIL as a therapy for lung CAncer) trial which is funded through the Medical Research Council Developmental Pathway Funding Scheme. My research interest is focused around driving promising novel therapies from the bench to the clinic with particular expertise in cell therapies. I am also interested in using a clinical trial setting to further develop our understanding of the use of cellular therapies with particular reference to improving their therapeutic efficacy.

Lauren H. Sansing, MD, MS, FAHA

Dr. Sansing’s laboratory investigates the role of immune responses after intracerebral hemorrhage in experimental murine in vivo and in vitro models, as well as ex vivo models using patient leukocytes and surgical specimens. As a physician-scientist, her goal is to identify the pathological processes that lead to brain injury in our patients, as well as the processes that aid in recovery and repair. With this understanding, we can develop targeted therapeutics to minimize injury after stroke and maximize recovery. She is committed to furthering our understanding of the pathophysiology of acute brain injury across the research spectrum from preclinical models through clinical trials. She also loves to work with students and fellows in lab asking fun/big picture questions about immune responses in the brain. She is a frequently invited speaker at national and international meetings and codirects the Yale Investigative Neurology program for physician-scientist training. She was awarded the American Society for Clinical Investigation Young Physician-Scientist Award in 2013 and the American Academy of Neurology Michael S. Pessin Stroke Leadership Prize in 2015.
PARTICIPANTS BIOGRAPHIES

Paolo Serafini, PhD

Dr. Paolo Serafini is an Assistant Professor of Microbiology and Immunology and Otolaryngology at the University of Miami. He graduated from University of Padova in molecular biology, earned a PhD in Immunology, Oncology and Surgical science, and performed a postdoctoral fellowship in tumor immunology and tolerance at the Johns Hopkins University.

Dr. Serafini’s major achievements is the cellular definition and molecular characterization of immune regulatory cells, now called myeloid-derived suppressor cells (MDSCs), that play a key role in restraining antitumor immunity and promoting metastases, but are emerging also as important players in controlling autoimmunity. Dr. Serafini’s group in the last years developed different nanoparticles that preferentially target MDSCs in vivo allowing the fine in vivo dissection of myeloid cell biology in tumor and autoimmune disease setting. His work has been cited more than 6000 times. Dr. Serafini identified different pharmaceutical targets on MDSCs that showed promises in clinical trial. Dr. Serafini is president of Vipp consulting, scientific founder and member of the advisory board for Nanovax inc, and consultant for different pharmaceutical industries.

Ronan Swords, MD, PhD, FRCPI, FRCPATH

Ronan Swords graduated with honors from the National University of Ireland, Galway, in 2000. After his internal medicine residency, he completed a 5 year hematology fellowship program graduating as a fellow of the Royal College of Physicians of Ireland, and the Royal College of Pathologists in London. In 2008 he moved to the US, and completed advanced fellowship training in drug development at the University of Texas Health Center in San Antonio. In 2012 he completed his PhD training at the same institution where his laboratory studies focussed primarily on post-translational modification pathways in acute myeloid leukemia. Shortly after finishing his PhD, he moved to the University of Miami, where he directs the adult leukemia program and also serves as co-director for both the cancer epigenetics and phase I drug development programs. His research is focussed on developing novel, safer and more effective therapeutics for acute leukemia. His work is funded by the NCI and private foundations. He has published over 100 peer reviewed papers and serves on the editorial boards of prestigious journals. Currently, his group is studying the translational potential of new epigenetic targets including LSD1, NEDD8, TET2, ASXL1 and others, for patients with acute myeloid leukemia.
PARTICIPANTS BIOGRAPHIES

Alice Tomei, PhD

Dr. Tomei is an Assistant Professor in the department of Biomedical Engineering of the University of Miami and the director of the Islet Immunoengineering Laboratory (www.tomeilab.com) at the University of Miami Diabetes Research Institute. Dr. Tomei’s background uniquely combines expertise in bioengineering and immunology and she is applying her skills to the development of novel immunoengineering platforms to prevent rejection after islet transplantation and to promote antigen-specific tolerance for a cure of type-1 diabetes. To that end, her strategy is to design and develop novel technology platforms with strong clinical translation potential that are supported by solid mechanistic studies in preclinical models of type-1 diabetes that are relevant to the human disease. Her enthusiastic commitment to type-1 diabetes cure-focused research is matched by a solid track record of academic achievements and translational efforts. She has trained in the best engineering school in Italy, the Politecnico di Milano. Then, she conducted her PhD work at the École Polytechnique Fédérale de Lausanne (EPFL), Switzerland, under the mentorship of Dr. Melody Swartz, world leader in lymphatic and cancer mechanobiology. Then, Dr. Tomei conducted her postdoctoral fellowship at EPFL in the laboratory of Dr. Jeffrey Hubbell, world leader in molecular engineering, and in collaboration with Dr. Cherie Stabler, a leader in diabetes bioengineering research. In recognition of these accomplishments, in 2012, Dr. Tomei was invited to become part of the prestigious Juvenile Diabetes Research Foundation (JDRF) encapsulation consortium, which gathers the world leaders in islet encapsulation and transplantation, and promotes collaborations, sharing of data and protocols with the overall goal of advancing the field. Dr. Tomei has presented her research work at several international conferences, including an invited oral presentation at the Key Opinion Leaders Meeting on Stem Cell Derived Beta Cells at Harvard Medical School in Boston in October 2016, an oral presentation at the annual meeting of the Immunology of Diabetes Society in San Francisco in January 2017, and an invited oral presentation at the annual meeting of the international society for cellular therapy (ISCT) in the workshop on special advancements in cellular therapies and regenerative medicine in digestive diseases in London, in May 2017 and an invited oral presentation at the annual meeting of the American Diabetes Association in San Diego in June 2017. Finally, she was invited to serve as member of the grant review panels for both the JDRF and for the California Institute for Regenerative Medicine (CIRM). Dr. Tomei’s research has been funded by the Diabetes Research Institute Foundation, the iacocca Family Foundation, the Juvenile Diabetes Research Foundation (JDRF), the Helmsley Trust, the Tronchetti Provera Foundation, the Children with Diabetes Foundation, the Department of Defense, and the National Institute of Health, including a recently awarded JDRF career development award. In recognition of her research productive, Dr. Tomei was recently awarded the University of Miami College of Engineering 2016 Eliahu I. Jury Early Career Research Award for obtaining major research grants. These important achievements further highlight her recognition in the field of immunoengineering for type-1 diabetes.

Lars Vereecke, PhD

I obtained my PhD at Gent university in 2011 on innate immunity in gastrointestinal homeostasis, and recently obtained an assistant-professor position (October 2016) at the Department of Rheumatology headed by Prof. Dirk Elewaut, at the Ghent University Hospital. Our lab is part the ‘Center for Inflammation Research’ (IRC), a VIB department (Flemish Institute for Biotechnology). My main research focus is understanding the complex interactions between the intestinal microbiota and the host immune system, both locally and systemically (e.g. during arthritis development or cancer development). In this respect, I am currently coordinating the start-up of the first Belgian ‘germfree and gnotobiotic mouse facility’ at Ghent University. I am also coordinator of a research consortium at Ghent University focusing on intestinal inflammation the ‘Ghent Gut Inflammation Group’ (GGIG). I have a broad general interest in immunology and general health related science. In addition, I am teaching ‘molecular cell biology’ and ‘biomedical physiology’ at Ghent University.
Christiaan Vinckers, MD, PhD

My overall research objective is to investigate the neurobiological background of stress resilience and vulnerability including (epi)genetic, neuroendocrine, and brain circuitry factors. I have obtained degrees in Pharmacy, Medicine and Law. My preclinical research concerned the genetic and molecular basis of stress reactivity using pharmacological, genetic and molecular techniques. With over 15 peer-reviewed publications and several international collaborations, this led to a cum laude PhD thesis in 2009. During my study of Pharmacy, subsequent PhD training, and my study of Medicine, I saw a great need for effective treatment options in psychiatric patients which convinced me to start my psychiatry residencies. In daily practice, I diagnose and treat patients with depression, schizophrenia, and bipolar disorder which directly links my fundamental research activities to a clinical setting. It is my drive is to look for solutions in both fundamental preclinical and applied clinical research and promote the exchange of ideas between those two research approaches. My research has contributed how (traumatic) stress increases the risk for psychiatric disorders and helped to identify who is (not) at risk. I am currently involved in various epidemiological and experimental studies, examining both genetic and neuroimaging parameters. I have obtained funding from various sources such as the Brain Foundation, the Dutch Government and the Rudolf Magnus Brain Center.

Andrew Wee Kien Han, MBBS (S'pore), MMed (Fam Med), MCI (NUS), FCFP(S), FAMS

Dr Andrew Wee is a Family Physician of SingHealth Polyclinics (SHP), Marine Parade. He obtained his MBBS (Singapore) degrees in 1996 and MMed (Family Medicine) in 2002. He received his Collegiate Fellowship from the College of Family Physicians Singapore in 2011 and went on to complete the Master of Clinical Investigation from NUS-YLLSOM in 2012. In October 2014, he was part of the first batch of family physicians to be recognised and received as a Fellow of the Academy of Medicine Singapore (FAMS). His accolades for medical excellence include the Star Award – Singapore Health Quality Service Award 2014 and Star Award – Eastern Health Alliance Caring Awards 2014.

Dr Wee’s passion for research started at a very young age, having created his very own mini-biology lab at home. Apart from his innate spirit of inquiry, his deep passion for public interest and safety also spurs him to do research. He advocates the synergistic combination of clinical quality with research to improve patient care.

Dr Wee is a recipient of the 2014 ExxonMobil-NUS Research Fellowship and 2015 NMRC Clinician Investigator Salary Support Programme (CISSP) that afford him protected time to undertake noteworthy research projects in the polyclinics.

He is also an active member of the SHP Research Committee (ASPIRE) and has a keen interest in the diverse fields of botany, zoology, pharmacognosy, psychiatry, chronic diseases, obesity, nephrology, cancer biology and ageing.

Pastimes include, trekking, wood-burning (art), nurturing carnivorous plants from the Family: Nepenthaceae, carpentry, DIY activities, visiting hardware shops trying to look like a professional tradesman (when he is not), etc.

Ever a firm believer of the axiom “you are what you eat” and that nutrition is the crux of primary prevention, Dr Wee is currently involved in several research projects involving lifestyle and nutritional aspects in the elderly and collaborates very closely with tertiary hospitals on these.
### Partners

1. The University of Arizona
2. University of Miami Clinical & Translational Science Institute
3. SingHealth Duke NUS Academic Medical Centre
4. Stanford University
5. UMC Utrecht

### Supporters

1. Nature Medicine
2. Nature Medicine Biotechnology
3. Nutricia Research
4. Parent Project Muscular Dystrophy
5. UCL